Under the patronage of H.H. Sheikh Hamdan Bin Rashid Al ... Program.pdf · 19th Asia Paciﬁc...

October 16 - 20, 2017 | Dubai World Trade Center - U.A.E.

19th Asia Pacific League of Associationsfor Rheumatology Congress - APLAR 2017

3rd Annual Emirates Society for Rheumatology - ESR

www.aplar2017.com

16 - 20 October Dubai, U.A.E.

ا�مارات جمعية مراض المفاصل والروماتيزم

Under the patronage of H.H. Sheikh Hamdan Bin Rashid Al Maktoum,Deputy Ruler of Dubai, UAE Minister of Finance, President of Dubai Health Authority

تحــت رعایــة ســمو الشـــــیخ حــمــــدان بــن راشـــــد آل مــكـــتوم،نائــب حاكــم دبــي، وزیــر المالیــة، رئیــس هیئــة الصحــة بدبــي

71CME CREDITS

2

Dear Colleagues & Friends,

It is a pleasure to invite you to join us at the APLAR 2017 in Dubai.

Wide-ranging in its approach and comprehensive in scope, APLAR 2017 will present a vital scientific programme of high-level plenaries by a distinguished group of international, regional, and national experts, interactive symposia on contemporary trends as well as symposia organized by Special Interest Groups of APLAR, a review course, poster discussion and debates on hot topics.

Thus, the 2017 Conference will need the collaboration and cooperation of individuals from many rheumatologists in the Asia Pacific region and from all over the world.

The Congress will offer plenty of networking opportunities, providing you with the opportunity to meet and interact with the practitioners and clinicians, academics and scientists, nurses and allied health professionals as well as sponsors and exhibitors.

We will also take some time off from the future of rheumatology to celebrate the camaraderie of the congress with a lavish social programme, and I look forward to meeting each and every one of you in the global city and business hub at Dubai, a city known for its luxury shopping, ultramodern architecture and a lively nightlife scene.

Yours sincerely,

Prof Kazuhiko YamamotoPresident, APLAR

Welcome Address by Aplar President

WELCOME MESSAGES

3

Dear Friends and Colleagues,

It is with great pleasure and anticipation that the Organizing Committee of APLAR extends a cordial invitation to attend the “19th Asia Pacific League of Associations for Rheumatology Congress APLAR 2017” in collaboration with the Emirates Society of Rheumatology (ESR)that will be held from October 16-20, 2017 in Dubai UAE at the Dubai world Trade Center.

This Congress is a not to be missed event as it will be hosted in the Magical and Vibrant city of Dubaibrining up-to-the-minute insight and updates on the latest in the field of Rheumatology, will provide a challenging scientific program in the form of plenary lectures, scientific sessions; interactive symposiums, a huge exhibition and is expected to bring high attendance from the region with prominent speakers who will master the latest updates in Rheumatology.

This event is aimed at transforming the way we operate as Rheumatologists in the hope of continuously improving our ability to perform and meet our daily challenges in our field and excel despite setbacks. In this aim, we will all be very proud of where we are today and excited about where we are headed with our research.

In closing, we not only want to offer you a unique opportunity but would like to thank you for helping us shape the future in the field of Rheumatology.

Looking forward to seeing you in Dubai!

Dr. Waleed AlShehhiPresident of APLAR 2017 Congress

Welcome Address by Congress Chairman

WELCOME MESSAGES

4

• PresidentProfessor Kazuhiko YamamotoTokyo, Japan

• Vice PresidentsProfessor Worawit LouthrenooChiangmai, Thailand

Professor Yoshiya TanakaKitakyushu, Japan

• TreasurerProfessor Debashish DandaVellore, India

• President ElectProfessor Syed Atiqul HaqDhaka, Bangladesh

• Immediate Past PresidentProfessor Kevin PileSydney, Australia

• Secretary GeneralProfessor Wen-Chan TsaiKaohsiung, Taiwan

• Deputy Secretary GeneralProfessor Chi-Chen ChangTaipei, Taiwan

EXECUTIVE COMMITTEE

5

• President ElectProfessor Syed Atiqul HaqDhaka, Bangladesh

• Immediate Past PresidentProfessor Kevin PileSydney, Australia

• Secretary GeneralProfessor Wen-Chan TsaiKaohsiung, Taiwan

• Deputy Secretary GeneralProfessor Chi-Chen ChangTaipei, Taiwan

SCIENTIFIC COMMITTEE

President of the Emirates Society for Rheumatology (ESR)ESR Board MemberChair of the ESR Scientific Committee ESR Board MemberESR Board MemberESR Board MemberESR Board MemberESR Board Member

• Chair:Prof. Zhanguo Li, China

• Members:Prof. CS Lau, Hongkong, ChinaProf. Lai-Shan Tham, Hongkong, ChinaDr. Laniyati Hamijoyo, IndonesiaProf. Sakae Tanaka, JapanProf. Tsutomu Takeuchi, JapanProf. Katsunori Ikari, JapanProf. Yan Zhao, ChinaProf. James Wei, TaiwanA/Prof. Keith Lim, AustraliaProf. Debasish Danda, IndiaDr. Michael Tee, Philippines

EDUCATION COMMITTEE• Chair:Prof. C S Lau, Hong Kong , China

STANDING COMMITTEES• COPCORD

• Co-Ordinator:Prof. Fereydoun Davatchi, Iran

SUB COMMITTEES• International Affairs Committee

• Chair: Prof. Lai-Shan Tam, Hong Kong, China

UAE (ESR) ORGANIZING COMMITTEE

Dr. Waleed AlShehhi Dr. Mustafa Al Izzi Dr. Atheer Al-Ansari Dr. Humeira Badsha Dr. Imad JassimDr. Bhavna Khan Dr. Ayman MasriDr. ElSadeg Sharif

• Vice Chair: Prof. Yeong-Wook Song , Korea

COMMITTEES

6

Abdullatif Al-Arfaj Adeeba Al-HerzAhmad ALEniziAhmed AbogamalAla’ AlHeresh Alhussain AsiriAli JawadAlice LeahyAman SharmaAndrew ÖstörAnselm MakAnwar Samhari ArshadArvind ChopraAsad ZomaAtheer Al-AnsariAvinash GurbaxaniBassel El-ZorkanyBasel MasriBasil FathallaBhavna KhanCanchi BalakrishnanCaifeng LiCarol LangfordChit SoeChristine BernalChristopher DentonDaniel AletahaDaniel TM ChanDavid KaneDebashish DandaDiamant ThaciEduardo Mysler Edward RoddyEsperanza NaredoEster Gonzales-PensergaEun Young LeeFereydoun DavatchiFouad Fayad Gamal Ibrahim

Georg SchettGhita HarifiGrace KimHaider Al-AttiaHani AlMoallimHumeira BadshaHussein HalabiIain McinnesIan ReidIngrid MollerJamal Al-SalehJames Cheng-Chung WeiJohannes W.J. Bijlsma John AxfordJohn CushJuma AlKaabiKarim ZunaidKaty Leung Ying YingKazuhiko Yamamoto Kevin PileKhalid AlnaqbiKhouloud SalehKuang-Yung HuangKusuki NishiokaLai-Shan TamLeong Khai PangLisa Christopher-StineMark GolovizninMasataka KuwanaMathew AshishMaurizio CutoloMengtao Li, Xiaofeng ZengMichael TeeMichelle Petri Mikkel ØstergaardMitsumasa KishimotoMohammad FarghalyMonika ØstensenMuhammed Haroun

Munther Khamashta Mustafa El IzziNafaja Al HasaniNelly ZiadeNighat Mir AhmadNizar Abdulateef Noriko YoshimuraPaul Bird Paul EmeryPeter BalintPeter NashPeter TaylorPhilip HelliwellPiergiorgio NeriPrakash PispatiRamnath MisraReem AbdwaniRohini HandaSalwa AlCheikhSami Salman Sandra NavarraSapan PandyaSlavica ProdanovićSuad HannawiSulaiman Al-MayoufSyed Atiqul HaqTimothy R. OrchardTore Kristian KvienTsutomu TakeuchiVed ChaturvediWaleed AlShehhiXinping Tian Yasser El MiedanyYoshihiro Arimura Yoshiya TanakaYossra SulimanYukinori OkadaZhanguo Li

KSAKuwaitKuwaitEgyptJordanKSAUKUKIndiaAustraliaMalaysiaMalaysiaIndiaUKUAEUAEEgyptJordanUAEUAEIndiaChinaUSAMyanmarPhillipinesUKAustriaChinaIrelandIndiaGermanyArgentinaUKSpainPhillipinesKoreaIranLebanonUAE

GermanyUAEUSAUAEKSAUAEKSAUKNew ZelandSpainUAETaiwanThe NetherlandsUKUSAOmanUKSingaporeJapanAustraliaUAEKuwaitTaiwanJapanChinaSingaporeUSARussiaJapanIndiaItalyChinaPhillipinesUSADenmarkJapanUAENorwayIreland

UAEUAEUAELebanonPakistanIraqJapanAustraliaUKHungaryAustraliaUKUKItalyIndiaIndiaOmanIndiaSyriaIraqPhillipinesIndiaSerbiaUAEKSABangladeshUKNorwayJapanIndiaUAEChinaUKJapanJapanEgyptJapanChina

FACULTY LIST

7

Dubai is located on the Eastern coast of the Arabian Peninsula, in the south west corner of the Arabian Gulf. It is extremely well known for its warm hospitality and rich cultural heritage, and the Emirati people are welcoming and generous in their approach to visitors. With year-round sunshine, intriguing deserts, beautiful beaches, luxurious hotels and shopping malls, fascinating heritage attractions and a thriving business community, Dubai receives millions of leisure and business visitors each year from around the world.

Dubai Economy: The past few decades have witnessed incredible growth throughout all sectors of the Dubai economy. The emirate’s government is constantly working to improve its commercial transparency and introduce dynamic regulations that aid the formation of small and medium enterprises. Dubai’s economy is no longer reliant on oil, but is more diversified, relying heavily on trade, services and finance sectors. With its central geographic location between Asian and European markets, Dubai has worked hard to establish itself as an integral part of the global trade mechanism. Its central location has also allowed Dubai to become a popular and accessible tourist destination.

ABOUT DUBAI

8

GENERAL INFORMATION

Opening Ceremony Closing CeremonyDate: Tuesday, 17 October, 2017 Date: Friday, 20 October, 2017Time: 17:00 -18:00 Time: 14:45 - 15:15Venue: Sheikh Rashid Hall F Venue: Sheikh Rashid Hall FGuest of Honor: H.H. Sheikh Hamdan Bin Rashid Al MaktoumDress Code: Business Casual

Welcome Reception Date: Tuesday, 17 October, 2017Time: 18:00Venue: Sheikh Rashid Hall E (Exhibition Hall)

Dinners1. Presidential Dinners (By Invitation Only) 2. Conference Dinner 3. Dinner (By Invitation Only)Date: Tuesday, 17 OctoberTime: 20:30Dress Code: Smart CasualVenue: World Trade Club

Congress VenueDubai World Trade Center - Sheikh Rashid Halls

Registration and Information 2 Stations for registration and information desks are located as per below:Station 1 facing Hall A / E (Ground Floor)Station 2 facing Hall F / C & D (Ground Floor)Date Time 16 October 08:00 -17:00 17 October 07:00 -17:30 18 October 06:30 -19:00 19 October 06:30 -19:00 20 October 07:30 -15:30

Speakers’ Ready Room (Organizer Office A - Ground Floor) Speakers’ Ready Room will operate according to the following hours:Date Time 16 October 08:00 -17:00 17 October 07:00 -17:30 18 October 06:30 -19:00 19 October 06:30 -19:00 20 October 07:30 -15:30

* Speakers are requested to access the speaker ready room 3 to 4 hours before their presentation* For those who are coming a day prior to their presentation, you are requested to give us the powerpointa day ahead

Date: Thursday, 19 OctoberTime: 20:30Dress Code: Smart CasualVenue: Bab Al Shams

Date: Wednesday, 18 OctoberTime: 20:30Dress Code: Smart CasualFee: 120 US $/per person Admission will be by invitation or by ticketVenue: Jumeirah Hotel Arena

9

GENERAL INFORMATION

Schedule Mantling Dismantling18 October 08:30 - 19:00 17 October 15:00 - 17:00 18 October 18:00 - 19:0019 October 08:30 - 19:00 18 October 19:00 - 20:00 19 October 18:00 - 19:0020 October 08:30 - 15:30 19 October 19:00 - 20:00 20 October 15:30 - 16:30

Tour Desk You may book your local sightseeing tours at the Tour Desk located at the ground floor at Dubai Trade World Center.

Poster Presentation Posters will be posted at the Exhibition Area - Sheikh Rashid Hall E

Mounting Supplies will be available at the poster area during the set-up period.

Coffee Breaks Coffee Breaks will be served at the exhibition area and are available at designated times.Refer to the detailed program

LunchLunches will be served during symposium timing. Refer to the detailed program

ExhibitionThe exhibition is located at the Ground Floor and the Basement Floor (-1)The opening hours are:17 October 16:00 - 19:30 18 October 08:30 - 19:0019 October 08:30 - 19:0020 October 08:30 - 15:15

Prayer RoomThe prayer room is located at C1 Floor

Language The official language of the Congress is English

Certificate of Attendance Certificate of attendance will be distributed at Registration Desks.

Personal PropertyPlease take good care of your personal belongings. Do not leave them unattended. The organizers and the Congress Secretariat will not be responsible for any loss or damage of your personal properties.

Smoking PolicyNo smoking areas will be provided

10

OPENING CEREMONY

TUESDAY, 17 OCTOBER 2017

Master of Ceremony Mrs. Rania Ali

Address of the Vice President, Prime Minister & the Ruler of Dubai H.H Sheikh Hamdan Bin Rashid Al Maktoum

Address of APLAR President Prof. Kazuhiko Yamamoto

Address of the President of EMA Association Ms. Mouza AlSuwaidi

Address of the Chairman of APLAR Scientific Committee Dr. Atheer Al Ansari

Address of ESR President and APLAR Co-Chair Dr. Waleed AlShehhi

Music Intervention: Al Ayala Dance

Official Opening of Exhibition followed by a Cocktail Reception

11

CLOSING CEREMONY

FRIDAY, 20 OCTOBER 2017

Address of the Chairman of Local Organising Committee Dr. Waleed AlShehhi

Address of the Chairman of Scientific Committee Prof. Yeong-Wook SongProf. Zhanguo Li

Address of the President of APLAR ProfKazuhiko Yamamoto

Celltrion Best Abstract Award Presentation Prof. Kazuhiko YamamotoDr. Waleed AlShehhiProf. Yeong-Wook SongProf. Zhanguo Li

Flag Handover From Dr. Waleed AlShehhi - ESR to Prof. Wen-Chan Tsai

Address of the Congress Chair of Aplar 2018 Taiwan Prof. Wen-Chan Tsai

End of Closing Ceremony

Enbrel® 50 mg Abbreviated Prescribing InformationPresentation: Enbrel® 50 mg solution for injection in pre-�lled pen or in pre-�lled syringe. Each pre-�lled pen or pre-�lled syringe contains 50 mg of Etanercept. Therapeutic indications Rheumatoid arthritis: Enbrel in combination with methotrex-ate is indicated for the treatment of moderate to severe active rheumatoid arthritis in adults when the response to disease-modifying antirheumatic drugs, including methotrexate (unless contraindicated), has been inadequate. Enbrel can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. Enbrel is also indicated in the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. Enbrel, alone or in combination with methotrexate, has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function. Juvenile idiopathic arthritis Treatment of polyarthritis (rheumatoid factor positive or negative) and extended oligoarthritis in children and adolescents from the age of 2 years who have had an inadequate response to, or who have proved intolerant of, methotrexate. Treatment of psoriatic arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, methotrexate. Treatment of enthesitis-related arthritis in adolescents from the age of 12 years who have had aninadequate response to, or who have proved intolerant of, conventional therapy. Enbrel has not been studied in children aged less than 2 years. Psoriatic arthritis: Treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying antirheumatic drug therapy has been inadequate. Enbrel has been shown to improve physical function in patients with psoriatic arthritis, and to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease. Axial spondyloarthritisAnkylosing spondylitis: Treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy. Non-radiographic axial spondyloarthritis: Treatment of adults with severe non-radiographic axial spondyloarthritis with objective signs of in�ammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, who have had an inadequate response to nonsteroidal anti-in�ammatory drugs (NSAIDs). Plaque psoriasis: Treatment of adults with moderate to severe plaque psoriasis who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapy, including ciclosporin, methotrexate or psoralen and ultraviolet-A light (PUVA) Paediatric plaque psoriasis: Treatment of chronic severe plaque psoriasis in children and adolescents from the age of 6years who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies. Dosage and Method of Administration Enbrel® treatment should be initiated and supervised by specialist physicians experienced in the diagnosis and treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, plaque psoriasis or paediatric plaque psoriasis. Enbrel® is administered by subcutaneous injection. Patients treated with Enbrel® should be given the Patient Alert Card. Rheumatoid arthritis, Psoriatic arthritis, ankylosing spondylitis and non-radiographic axial spondyloarthritis: The recommended dose is 25 mg given twice a week or 50 mg Enbrel® administered once weekly. For all of the above indications, available data suggest that a clinical response is usually achieved within 12 weeks of treatment. Continued therapy should be carefully reconsidered in a patient not responding within this time period. Plaque psoriasis: The recommended dose is 25 mg administered twice weekly or 50 mg once weekly. Alternatively, 50 mg given twice weekly may be used for up to 12 weeks followed, if necessary, by a dose of 25 mg twice weekly or 50 mg once weekly. Treatment with Enbrel should continue until remission is achieved, for up to 24 weeks, Continuous therapy beyond 24 weeks may be appropriate for some adult patients. Treatment should be discontinued in patients who show no response after 12 weeks. If re-treatment with Enbrel is indicated, the same guidance on treatment duration should be followed. The dose should be 25 mg twice weekly or 50 mg once weekly. Special populations Renal and hepatic impairment No dose adjustment is required. Older people(≥ 65 years). No dose adjustment is required. Posology and administration are the same as for adults 18-64 years of age Paediatric population The dosage of Enbrel is based on body weight for paediatric patients. Patients weighing less than 62.5 kg should be accurately dosed on a mg/kg basis using the powder and solvent for solution for injection presentations or the powder for solution for injection presentations( see below for dosing for speci�c indication). Patients weighing 62.5 kg or more, may be dosed using �xed-dose pre-�lled syringe or pre-�lled pen. Juvenile Idiopathic arthritis The recommended dose is 0.4 mg/kg (up to a maximum of 25 mg per dose), given twice weekly as a subcutaneous injection with an interval of 3-4 days between doses or 0.8mg/kg (up to a maximum of 50 mg per dose) given once weekly. Discontinuation of treatement should be considered in patients who show no response after 4 months. The 10 mg vial strength may be more appropriate for administration to children with JIA below the weight of 25 kg. No formal clinical trials have been conducted in children aged 2 to 3 years. However, limited safety data from a patient registry suggest that the safety pro�le in children from 2 to 3 years of age is similar to that seen in adults and children aged 4 years and older, when dosed every week with 0.8 mg/kg subcutaneously. There is generally no applicable use of Enbrel in children aged below 2 years in the indication juvenile idiopathic arthritis. Pediatric plaque psoriasis (age 6 years and above) The recommended dose is 0.8 mg/kg (up to a maximum of 50 mg per dose) once weekly for up to 24 weeks. Treatment should be discontinued in patients who show no response after 12 weeks. If re-treatment with Enbrel is indicated, the above guidance on treatment duration should be followed. The dose should be 0.8 mg/kg (up to a maximum of 50 mg per dose) once weekly. Contraindications: Hypersensitivity to the active substance or to any of the excipients. Sepsis or risk of sepsis. Treatment with Enbrel® should not be initiated in patients with active infections, including chronic or localised infections. Special warnings and precautions for use Infections: Patients should be evaluated for infections before, during, and after treatment with Enbrel®, taking into consideration that the mean elimination half-life of Etanercept is approximately 70 hours (range 7 to 300 hours). Physicians should exercise caution when considering the use of Enbrel in patients with a history of recurring or chronic infections or with underlying conditions that may predispose patients to infections such as advanced or poorly controlled diabetes. Patients who develop a new infection while undergoing treatment with Enbrel should be monitored closely. Administration of Enbrel should be discontinued if a patient develops a serious infection. Tuberculosis: Cases of active tuberculosis, including miliary tuberculosis and tuberculosis with extra-pulmonary location, have been reported in patients treated with Enbrel. Before starting treatment with Enbrel® , all patients must be evaluated for both active and inactive (‘latent’) tuberculosis. Allergic reactions: The needle cover of the pre-�lled syringe and the needle cap of the pre-�lled pen contain latex that may cause hypersensitivity reactions when handled by or when Enbrel® is administered to persons with known or possible latex sensitivity. Hepatitis B virus reactivation, Reactivation of hepatitis B in patients who were previously infected with the hepatitis B virus (HBV) and had received concomitant TNF-antagonists, including Enbrel, has been reported. This includes reports of reactivation of hepatitis B in patients who were anti-HBc positive but HBsAg negative. Patients should be tested for HBV infection before initiating treatment with Enbrel. For patients who test positive for HBV infection, consultation with a physician with expertise in the treatment of hepatitis B is recommended. Caution should be exercised when administering Enbrel in patients previously infected with HBV. These patients should be monitored for signs and symptoms of active HBV infection throughout therapy and for several weeks following termination of therapy. Adequate data from treating patients infected with HBV with anti-viral therapy in conjunction with TNF-antagonist therapy are not available. In patients who develop HBV infection, Enbrel should be stopped and e�ective anti-viral therapy with appropriate supportive treatment should be initiated. Worsening of hepatitis C: Enbrel® should be used with caution in patients with a history of hepatitis C. Solid and haematopoietic malignancies (excluding skin cancers) Based on current knowledge, a possible risk for the development of lymphomas, leukaemia or other haematopoietic or solid malignancies in patients treated with a TNF-antagonist cannot be excluded. Caution should be exercised when considering TNF-antagonist therapy for patients with a history of malignancy or when considering continuing treatment in patients who develop a malignancy Skin cancers Melanoma and non-melanoma skin cancer (NMSC) have been reported in patients treated with TNF-antagonists, including Enbrel. Periodic skin examination is recommended for all patients, particularly those with risk factors for skin cancer. Malignancies have also been reported with use of Enbrel. Congestive heart failure Physicians should use caution when using Enbrel in patients who have congestive heart failure (CHF). Vaccinations: Live vaccines should not be given concurrently with Enbrel. No data are available on the secondary transmission of infection by live vaccines in patients receiving Enbrel Vaccination in Paediatric Population: If possible, children should be up to date with all vaccinations before using Enbrel. Some vaccines, such as oral polio vaccine, should not be given while using Enbrel. Diabetes: There have been reports of hypoglycemia following initiation of Enbrel in patients receiving medication for diabetes, necessitating a reduction in anti-diabetic medication in some of these patients.Pregnancy There are no studies of Enbrel in pregnant women thus, the use of Enbrel during pregnancy is not recommended. Breast-feeding: Etanercept has been reported to be excreted in human milk following subcutaneous administration. Because immunoglobulins, in common with many medicinal products, can be excreted in human milk, a decision must be made whether to discontinue breast-feeding or to discontinue Enbrel therapy, taking into account the bene�t of breast-feeding for the child and the bene�t of therapy for the woman. Fertility: Preclinical data about peri- and postnatal toxicity of Etanercept and of e�ects of etanercept on fertility and general reproductive performance are not available. Interaction with other medicinal products and other forms of interaction Concurrent treatment with anakinra and abatacept is not recommended. Physicians should use caution when considering combination therapy with sulfasalazine. Live vaccines should not be given concurrently with Enbrel®. Overdosing No dose-limiting toxicities were observed during clinical trials of rheumatoid arthritis patients. Undesirable e�ects The very common undesirable e�ects were: Infections (including upper respiratory tract infections, bronchitis, cystitis, bladder infections, and skin infections) and Injection site reactions (including bleeding, bruising, erythema, itching, pain, and swelling). Common undesirable e�ects include allergic reactions, Pruritus, Fever, and autoantibody formation. Pharmaceutical precautions Store in a refrigerator (2°C - 8°C). Do not freeze. Keep out of the reach and sight of children. Keep the pre-�lled syringe/pens in the outer carton in order to protect from light. Comprehensive instructions for administration are given in the insert lea�et. Reference: SmPC dated December 2014. Date of the document: 22 November 2016. It is recommended that patients read patients insert lea�et.

References:1. Furuya H, Kasama T, Isozaki T, et al. E�ect of TNF antagonists on the productivity of daily work of patients with rheumatoid arthritis. J Multidicip Healthc. 2013; 6:25-30. Epub 2013 Jan 14.2. Committee for Medical Products for Human Use (CHMP). Enbrel (etanercept) Assessment Report EMA/548283/2012. European Medicines Agency. 1 June 2012.3. Enbrel (etanercept). Product monograph. Regulatory A�airs Canada, Date of Revision: November 1, 2013. Consulted in October 2014. https://www.amgen.ca/Enbrel_PM.pdf4. Enbrel (etanercept). Summary of product charachteristics. Revision Date: December, 2014.

The very common undesirable e�ects were: Infections (including upper respiratory tract infections, bronchitis, cystitis, bladderinfections, and skin infections) and Injection site reactions (includ-ing bleeding, bruising, erythema, itching, pain, and swelling).Common undesirable e�ects include allergic reations, Pruritus, Fever, and autoantibody formation4

Available as 50-mg pre-�lled syringe, 25mg pre-�lled syringe and MyClic® 50mg pre-�lled pen*Recommended dose in RheumatoidArthritis is 50mg once weekly, or 25mg twice weekly4

*: according to the availability in each country.

PP-E

NB-

GLM

-010

2

Enbrel® 50 mg Abbreviated Prescribing InformationPresentation: Enbrel® 50 mg solution for injection in pre-�lled pen or in pre-�lled syringe. Each pre-�lled pen or pre-�lled syringe contains 50 mg of Etanercept. Therapeutic indications Rheumatoid arthritis: Enbrel in combination with methotrex-ate is indicated for the treatment of moderate to severe active rheumatoid arthritis in adults when the response to disease-modifying antirheumatic drugs, including methotrexate (unless contraindicated), has been inadequate. Enbrel can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. Enbrel is also indicated in the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. Enbrel, alone or in combination with methotrexate, has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function. Juvenile idiopathic arthritis Treatment of polyarthritis (rheumatoid factor positive or negative) and extended oligoarthritis in children and adolescents from the age of 2 years who have had an inadequate response to, or who have proved intolerant of, methotrexate. Treatment of psoriatic arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, methotrexate. Treatment of enthesitis-related arthritis in adolescents from the age of 12 years who have had aninadequate response to, or who have proved intolerant of, conventional therapy. Enbrel has not been studied in children aged less than 2 years. Psoriatic arthritis: Treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying antirheumatic drug therapy has been inadequate. Enbrel has been shown to improve physical function in patients with psoriatic arthritis, and to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease. Axial spondyloarthritisAnkylosing spondylitis: Treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy. Non-radiographic axial spondyloarthritis: Treatment of adults with severe non-radiographic axial spondyloarthritis with objective signs of in�ammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, who have had an inadequate response to nonsteroidal anti-in�ammatory drugs (NSAIDs). Plaque psoriasis: Treatment of adults with moderate to severe plaque psoriasis who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapy, including ciclosporin, methotrexate or psoralen and ultraviolet-A light (PUVA) Paediatric plaque psoriasis: Treatment of chronic severe plaque psoriasis in children and adolescents from the age of 6years who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies. Dosage and Method of Administration Enbrel® treatment should be initiated and supervised by specialist physicians experienced in the diagnosis and treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, plaque psoriasis or paediatric plaque psoriasis. Enbrel® is administered by subcutaneous injection. Patients treated with Enbrel® should be given the Patient Alert Card. Rheumatoid arthritis, Psoriatic arthritis, ankylosing spondylitis and non-radiographic axial spondyloarthritis: The recommended dose is 25 mg given twice a week or 50 mg Enbrel® administered once weekly. For all of the above indications, available data suggest that a clinical response is usually achieved within 12 weeks of treatment. Continued therapy should be carefully reconsidered in a patient not responding within this time period. Plaque psoriasis: The recommended dose is 25 mg administered twice weekly or 50 mg once weekly. Alternatively, 50 mg given twice weekly may be used for up to 12 weeks followed, if necessary, by a dose of 25 mg twice weekly or 50 mg once weekly. Treatment with Enbrel should continue until remission is achieved, for up to 24 weeks, Continuous therapy beyond 24 weeks may be appropriate for some adult patients. Treatment should be discontinued in patients who show no response after 12 weeks. If re-treatment with Enbrel is indicated, the same guidance on treatment duration should be followed. The dose should be 25 mg twice weekly or 50 mg once weekly. Special populations Renal and hepatic impairment No dose adjustment is required. Older people(≥ 65 years). No dose adjustment is required. Posology and administration are the same as for adults 18-64 years of age Paediatric population The dosage of Enbrel is based on body weight for paediatric patients. Patients weighing less than 62.5 kg should be accurately dosed on a mg/kg basis using the powder and solvent for solution for injection presentations or the powder for solution for injection presentations( see below for dosing for speci�c indication). Patients weighing 62.5 kg or more, may be dosed using �xed-dose pre-�lled syringe or pre-�lled pen. Juvenile Idiopathic arthritis The recommended dose is 0.4 mg/kg (up to a maximum of 25 mg per dose), given twice weekly as a subcutaneous injection with an interval of 3-4 days between doses or 0.8mg/kg (up to a maximum of 50 mg per dose) given once weekly. Discontinuation of treatement should be considered in patients who show no response after 4 months. The 10 mg vial strength may be more appropriate for administration to children with JIA below the weight of 25 kg. No formal clinical trials have been conducted in children aged 2 to 3 years. However, limited safety data from a patient registry suggest that the safety pro�le in children from 2 to 3 years of age is similar to that seen in adults and children aged 4 years and older, when dosed every week with 0.8 mg/kg subcutaneously. There is generally no applicable use of Enbrel in children aged below 2 years in the indication juvenile idiopathic arthritis. Pediatric plaque psoriasis (age 6 years and above) The recommended dose is 0.8 mg/kg (up to a maximum of 50 mg per dose) once weekly for up to 24 weeks. Treatment should be discontinued in patients who show no response after 12 weeks. If re-treatment with Enbrel is indicated, the above guidance on treatment duration should be followed. The dose should be 0.8 mg/kg (up to a maximum of 50 mg per dose) once weekly. Contraindications: Hypersensitivity to the active substance or to any of the excipients. Sepsis or risk of sepsis. Treatment with Enbrel® should not be initiated in patients with active infections, including chronic or localised infections. Special warnings and precautions for use Infections: Patients should be evaluated for infections before, during, and after treatment with Enbrel®, taking into consideration that the mean elimination half-life of Etanercept is approximately 70 hours (range 7 to 300 hours). Physicians should exercise caution when considering the use of Enbrel in patients with a history of recurring or chronic infections or with underlying conditions that may predispose patients to infections such as advanced or poorly controlled diabetes. Patients who develop a new infection while undergoing treatment with Enbrel should be monitored closely. Administration of Enbrel should be discontinued if a patient develops a serious infection. Tuberculosis: Cases of active tuberculosis, including miliary tuberculosis and tuberculosis with extra-pulmonary location, have been reported in patients treated with Enbrel. Before starting treatment with Enbrel® , all patients must be evaluated for both active and inactive (‘latent’) tuberculosis. Allergic reactions: The needle cover of the pre-�lled syringe and the needle cap of the pre-�lled pen contain latex that may cause hypersensitivity reactions when handled by or when Enbrel® is administered to persons with known or possible latex sensitivity. Hepatitis B virus reactivation, Reactivation of hepatitis B in patients who were previously infected with the hepatitis B virus (HBV) and had received concomitant TNF-antagonists, including Enbrel, has been reported. This includes reports of reactivation of hepatitis B in patients who were anti-HBc positive but HBsAg negative. Patients should be tested for HBV infection before initiating treatment with Enbrel. For patients who test positive for HBV infection, consultation with a physician with expertise in the treatment of hepatitis B is recommended. Caution should be exercised when administering Enbrel in patients previously infected with HBV. These patients should be monitored for signs and symptoms of active HBV infection throughout therapy and for several weeks following termination of therapy. Adequate data from treating patients infected with HBV with anti-viral therapy in conjunction with TNF-antagonist therapy are not available. In patients who develop HBV infection, Enbrel should be stopped and e�ective anti-viral therapy with appropriate supportive treatment should be initiated. Worsening of hepatitis C: Enbrel® should be used with caution in patients with a history of hepatitis C. Solid and haematopoietic malignancies (excluding skin cancers) Based on current knowledge, a possible risk for the development of lymphomas, leukaemia or other haematopoietic or solid malignancies in patients treated with a TNF-antagonist cannot be excluded. Caution should be exercised when considering TNF-antagonist therapy for patients with a history of malignancy or when considering continuing treatment in patients who develop a malignancy Skin cancers Melanoma and non-melanoma skin cancer (NMSC) have been reported in patients treated with TNF-antagonists, including Enbrel. Periodic skin examination is recommended for all patients, particularly those with risk factors for skin cancer. Malignancies have also been reported with use of Enbrel. Congestive heart failure Physicians should use caution when using Enbrel in patients who have congestive heart failure (CHF). Vaccinations: Live vaccines should not be given concurrently with Enbrel. No data are available on the secondary transmission of infection by live vaccines in patients receiving Enbrel Vaccination in Paediatric Population: If possible, children should be up to date with all vaccinations before using Enbrel. Some vaccines, such as oral polio vaccine, should not be given while using Enbrel. Diabetes: There have been reports of hypoglycemia following initiation of Enbrel in patients receiving medication for diabetes, necessitating a reduction in anti-diabetic medication in some of these patients.Pregnancy There are no studies of Enbrel in pregnant women thus, the use of Enbrel during pregnancy is not recommended. Breast-feeding: Etanercept has been reported to be excreted in human milk following subcutaneous administration. Because immunoglobulins, in common with many medicinal products, can be excreted in human milk, a decision must be made whether to discontinue breast-feeding or to discontinue Enbrel therapy, taking into account the bene�t of breast-feeding for the child and the bene�t of therapy for the woman. Fertility: Preclinical data about peri- and postnatal toxicity of Etanercept and of e�ects of etanercept on fertility and general reproductive performance are not available. Interaction with other medicinal products and other forms of interaction Concurrent treatment with anakinra and abatacept is not recommended. Physicians should use caution when considering combination therapy with sulfasalazine. Live vaccines should not be given concurrently with Enbrel®. Overdosing No dose-limiting toxicities were observed during clinical trials of rheumatoid arthritis patients. Undesirable e�ects The very common undesirable e�ects were: Infections (including upper respiratory tract infections, bronchitis, cystitis, bladder infections, and skin infections) and Injection site reactions (including bleeding, bruising, erythema, itching, pain, and swelling). Common undesirable e�ects include allergic reactions, Pruritus, Fever, and autoantibody formation. Pharmaceutical precautions Store in a refrigerator (2°C - 8°C). Do not freeze. Keep out of the reach and sight of children. Keep the pre-�lled syringe/pens in the outer carton in order to protect from light. Comprehensive instructions for administration are given in the insert lea�et. Reference: SmPC dated December 2014. Date of the document: 22 November 2016. It is recommended that patients read patients insert lea�et.

References:1. Furuya H, Kasama T, Isozaki T, et al. E�ect of TNF antagonists on the productivity of daily work of patients with rheumatoid arthritis. J Multidicip Healthc. 2013; 6:25-30. Epub 2013 Jan 14.2. Committee for Medical Products for Human Use (CHMP). Enbrel (etanercept) Assessment Report EMA/548283/2012. European Medicines Agency. 1 June 2012.3. Enbrel (etanercept). Product monograph. Regulatory A�airs Canada, Date of Revision: November 1, 2013. Consulted in October 2014. https://www.amgen.ca/Enbrel_PM.pdf4. Enbrel (etanercept). Summary of product charachteristics. Revision Date: December, 2014.

The very common undesirable e�ects were: Infections (including upper respiratory tract infections, bronchitis, cystitis, bladderinfections, and skin infections) and Injection site reactions (includ-ing bleeding, bruising, erythema, itching, pain, and swelling).Common undesirable e�ects include allergic reations, Pruritus, Fever, and autoantibody formation4

Available as 50-mg pre-�lled syringe, 25mg pre-�lled syringe and MyClic® 50mg pre-�lled pen*Recommended dose in RheumatoidArthritis is 50mg once weekly, or 25mg twice weekly4

*: according to the availability in each country.

PP-E

NB-

GLM

-010

2

Where you get it THE JOURNAL

What you get Current Clinical Definitive

To subscribe: visit jrheum.org online or send in your completed coupon below

The Journal ofRheumatology

VOLUME 38

2011

jrheum.org

PRINTED IN CANADA – ISSN 0315-162X

2017

CVV

All subscriptions are for the calendar year. Renewals for print subscriptions received after May 31, 2017 will be charged an additional $10 per back issue. Back issues: 2 years including current year are available if in stock. Single copies are available at $30 each. Claims: US 2 months, elsewhere 4 months from issue date, e.g., March 1 and May 1, respectively, for the January Issue. PRIVACY POLICY: For details of our privacy policy, visit our website at www.jrheum.org.

For terms of access visit jrheum.org

$285 US

Print + Online$350 US

On request

$1025 US

$750 US

$550 US

$215 US

$120

Rates for 2017 calendar yearUSA/INTERNATIONAL

Online Only

Phone: (416) 967-5155Fax: (416) 967-7556

- Multiuser (IP ranges)- Basic-Plus (IP ranges)- Basic (up to 4 users)TRAINEES+

AIRMAIL (ADD)

$975 US

$700 US

$500 US

$150 US+

15

PRE-CONGRESS COURSES

SCIENTIFIC PROGRAM

Sheikh Rashid Hall A Sheikh Rashid Hall B

08:00 - 16:00 APLAR Musculoskeletal Ultrasound Workshop MRI Workshop

Sheikh Rashid Hall A Sheikh Rashid Hall B

09:00 - 17:00 APLAR MusculoskeletalUltrasound Workshop MRI Workshop

Sheikh Rashid Hall F Sheikh Rashid Hall C&D

16:00 - 17:00 Symposium Sponsored by Abbvie Symposium Sponsored by Janssen

Sheikh Rashid Hall F

17:00 - 18:00 Opening Ceremony

Sheikh Rashid Hall E (Exhibition Hall)

18:00 Welcome Reception

20:30 PRESIDENTIAL DINNER by Invitation Only

PROGRAM AT A GLANCE

Tuesday, 17October, 2017


Monday, 16October, 2017

Dubai Room C ( C1 Floor)

09:00 - 16:20 Aplar Review Course

16

PROGRAM AT A GLANCE

Wednesday, 18October, 2017

Scientific Program Symposium Networking Opportunities& Poster Viewing

Sheikh Rashid Hall F Sheikh Rashid Hall C & D Sheikh Rashid Hall A Sheikh Rashid Hall B

07:30 - 08:30 Genetic SIGBusiness Meeting SLE SIG Business Meeting RA SIG Business Meeting

08:30 - 09:15Combined Plenary Session I: Sheikh Rashid Hall F

Management of Inflammatory Joint DiseaseTore Kvien

09:15 - 10:00Combined Plenary Session II: Sheikh Rashid Hall F

Evolving Trends in of RA TreatmentsWaleed AlShehhi, Peter Nash & Eduardo Mysler

10:00 - 10:30 COFFEE BREAK & POSTER VIEWING

10:30 - 11:45 Symposium Sponsored by Lilly Symposium Sponsored by Pfizer

Sessions Spondyloarthritis (I),Co-Sponsored by SpA SIG Connective Tissue Diseases Rheumatoid Arthritis Oral Abstract Presentations

11:45 - 12:10

Mechanisms - BasedTreatment of SpA- Lessonsfrom Pathophysiology forModern Treatment of SpA

Georg Schett

Neuro - Immunologic Axisin Sjogren’s Syndrome

Sapan Pandya

The LERACS Study:Patient Preferences

Regarding RheumatoidArthritis Treatments

Fouad Fayad

Oral Abstract Presentations12:10 - 12:35

CardiovascularRisk Screening inSpondyloarthritis:

What Should We Doin Clinical Practice?

Lai-Shan Tam

SLE in PregnancyMonika Østensen

Towards Cure for RAOptimizing Therapy inInflammatory Arthritis

Yasser El Miedany

12:35 - 13:00Non-Radiographic Axial

Spondyloarthritis,Concept or Reality?

James Cheng-Chung Wei

Safety of TherapeuticAgents in pregnant

Women With AutoimmuneRheumatic Diseases (ARDs)

Bhavna Khan

Kuwait Registry forRheumatic Diseases on the

Wheel of SuccessAdeeba Al-Herz

13:00 - 14:30 Lunch SymposiumSponsored by Abbvie

Lunch SymposiumSponsored by NewBridge

Pharmaceuticals

Sessions Scleroderma

SLE - Improving TheOutcome of Systemic

Lupus Erythematosus,Co-Sponsored by SLE SIG

Psoriatic Arthritis& Related Disorders Oral Abstract Presentations

14:30 - 14:55Immunogenetics of

SclerodermaMasataka Kuwana

Lupus & MusculoskeletalSystem

Sandra Navarra

An Early Diagnosis ofPsoriatic Arthritis

Mitsumasa Kishimoto

Oral Abstract Presentations14:55 - 15:20Pulmornary Hypertension

in SclerodermaChristopher Denton

Treatment of LupusNephritis - Current Status

and Future DirectionsDaniel TM Chan

Approach to VasculiticDisorders

Ramnath Misra

15:20 - 15:45The Utility of Capilloroscopy

for Early Diagnosis andManagement of Scleroderma

Maurizio Cutolo

Long-term Outcome of SLEin China

What CSTAR Told us?Mengtao Li

Gout: Integrating Myths,Fact and Science

Rohini Handa

Dubai Room A (Level C1)07:30 - 08:30 Meet the Expert 1: Polymyalgia Rheumatica - John Axford

17



Sessions Myositis & Granuloma Connective TissueDiseases II

Osteoarthritis:Epidemiology and Basic Research in Asia-Pacific

Region, Co-Sponsored by OA SIG

Interstitial Lung Disease in Rheumatic Diseases

16:15 - 16:40Difficult Myositis:

A Case-Based ApproachLisa Christopher-Stine

The Use and Abuse of Autoantibodies in Clinical

Practice Munther Khamashta

The Role of Inflammation in Osteoarthritis

Katy Leung Ying Ying

Interstitial Lung Disease in Scleroderma

Christopher Denton

16:40 - 17:05Antisynthetase Syndrome,

Beyond Inflammatory Myositis

Hussein Halabi

Infection Associated Vasculitic

Aman Sharma

Epidemiology Of the Locomotive Syndrome: The Research on Osteoarthritis/

Osteoporosis Against Disability Study

Noriko Yoshimura

Interstitial Lung Disease in RA

Eun Young Lee

17:05 - 17:30 IgG4 Related DiseasesSalwa Al-Cheikh

Management of Rare and Difficult Infections in the

Lupus Patient C. Balakrishnan

OA in Asia Pacific- A WHO COPCORD Perspective

Arvind Chopra

Computer Assisted Diagnostic of ILD

Grace Kim

17:30 - 17:55Musculoskeletal Features

of SarcoidosisAli Jawad

Sjogren’s Syndrom UpdatesAlhussain Asiri

Osteoarthritis Disease Outcomes

Ester Gonzales-Penserga

Lung in LupusAla’ AlHeresh

17:55 - 18:55 SpA SIG Buisness Meeting OA SIG Business Meeting

20.30 CONFERENCE DINNER

PROGRAM AT A GLANCE



18

Thursday, 19October, 2017 Scientific Program Symposium Networking Opportunities

& Poster Viewing

PROGRAM AT A GLANCE


07:30 - 08:30 Vasculitis SIGBusiness Meeting


Why Should Rheumatologists Know Genetics?Kazuhiko Yamamoto


Update on Immuno-Pathogenesis of Axial SpondyloArthritisBassel El-Zorkany


10:30 - 11:45 Symposium Sponsored by Pfizer Symposium Sponsored by Abbvie

Sessions Arthritis, Practical Aspects Vaculitis / IntravascularCoagulation Paediatric Rheumatology I Oral Abstract Presentations

11:45 - 12:10Novel Bio Products and

Post Bio Strategy AgainstRheumatic Disease

Kusuki Nishioka

Clinical Pictures of Behcet’sDisease in Different Parts

of the WorldFereydoun Davatchi

Auto-InflammatoryDisease in Childhood

Caifeng Li


Kuwait Consensus onVaccine Use in People withInflammatory Rheumatic

DiseaseAhmad ALEnizi

CatastrophicAntiphosphoLipids

SyndromeMunther Khamashta

Familial Non-InflammatoryArthropathy

Sulaiman Al-Mayouf

12:35 - 13:00

Inflammation LinksCardiovascular Risk Factorsto Cardiovascular Disease

in Rheumatoid ArthritisSuad Hannawi

Diagnosis and Managementof Takayasu’s Arteritis - ASouth Asian Perspective

Debashish Danda

From Pediatric to Adult:Making Transition Easier

Christine Bernal

13:00 - 14:30 Lunch SymposiumSponsored by Novartis

Lunch SymposiumSponsored by Lilly

Sessions EULAR Symposium Osteoperosis & BoneHealth Genetic & Molecular (I) Oral Abstract Presentations

14:30 - 14:55Psoriatic Arthritis: CurrentTreatments Towards New

Strategies?Iain McInnes

Osteoporosis ManagementToday and in the Future

Ian Reid

The INTERSPA Study:Diagnostic Properties ofAnti-CD74 Antibodies in

Early Axial SpondyloarthritisNelly Ziade


Systemic Sclerosis(Scleroderma) New EULARGuidelines and Treatment

RecommendationsMaurizio Cutolo

Updates on the Diagnosisof Osteoporosis

Basel Masri

The Mysterious Triangle:HLA B27, Sacroiliac Joints

and Spondyloarthritis.Prakash Pispati

15:20 - 15:45EULAR Guidelines on

Treatment of RheumatoidArthritis

Johannes W.J. Bijlsma

MusculoskeletalManifestation of Vitamin DDeficiency, From Evidence

to PracticeAtheer Al-Ansari

Thymus Gland Immunologyin Rheumatic Diseases.Molecular, Cellular and

Clinical Levels.Mark Goloviznin

Dubai Room A (Level C1)07:30 - 08:30 Meet the Expert 2: Immunology Session - Masataka Kawana

19



SessionsCOPCORD &

Epidemiological Aspectsin Rheumatology

RA (II) Recommendation and Strategy of Treatment in Rheumatology Arthritis Co-Sponsored by RA SIG

Genetics in Rheumatology (II), Co-Sponsored by

Genetics SIGTherapeutics

16:15 - 16:40APLAR-COPCORD: The

Past, Present and Future Syed Atiqul Haq

New Pathways and Informatics Approaches to Target Discovery and

Application Iain McInnes

(16:15 - 16:50)

Genetic Risk Factors in Rheumatic Disease

Yukinori Okada(16:15 - 16:50)

Diet in Rheumatoid Arthritis Humeira Badsha

16:40 - 17:05Does Delay Matter in Early

Arthritis?Jamal Al-Saleh

Advances in Rheumatoid Arthritis

Paul Emery (16:50 - 17:15)

Linking APLAR Genetic Researchers Thru Ethical

Bio-Banking Michael Tee

(16:50 - 17:15)

The Wide Use of Rituximab in Rheumatology Practice:

Results of Systematic Literature Reviews

Hani AlMoallim

17:05 - 17:30Malignancy and Rheumatic

diseasesGamal Ibrahim

Early Diagnosis and Strategies of Deep

Remission in RA Zhanguo Li

(17:15 - 17:40)

Personalized Rheumatology - The Role

of the GenesLeong Khai Pang(17:15 - 17:40)

Challenges With Biologic Therapies

Mustafa Al Izzi

17:30 - 17:55

Central Nervous System Manifestations of

Neuropsychiatric Lupus: The Pakistani Experience

Nighat Mir Ahmad

Long Term Adherence of Etanercept in Iraqi Patients with Rheumatoid Arthritis:

A Five-Year Data from Local Registry

Nizar Abdulateef

17:55 - 18:55 Symposium Sponsoredby Chugai Pharma

The Chronic Disease Management

Patient Compliance,Patient Adherence

Patient ConcordanceMohammad Farghaly

20.30 DINNER by Invitation Only

Thursday, 19October, 2017 Scientific Program Symposium Networking Opportunities

& Poster Viewing

PROGRAM AT A GLANCE

20



Prevention and Treatment of Early Rheumatoid ArthritisJohannes W.J. Bijlsma


Approach to a Difficult RA PatientsJohn Cush


Sessions ACR Symposium Spondyloarthritis Non-Clinical Aspects in Rheumatology Oral Abstract Presentations

10:30 - 10:55Introduction

Carol Langford(10:30 - 10:35)

Long Term Remission in Axial Spa.

Ved Chaturvedi

Patterns of IgG Glycosylation Distinguishes Different Clinical Phenotypes of

Antiphospholipid Antibody Positivity

John Axford

Oral Abstract Presentations10:55 - 11:20New Therapies for SLE

Michelle Petri(10:35 - 11:10)

Beyond The Usual in Ankylosing Spondylitis

Haider Al Attia

Effects of Some Non Steroidal Anti-inflammatory Drugs (NSAIDs) on Ovulation

in WomenSami Salman

11:20 - 11:45Treatment of ANCA-Associated Vasculitis

Carol Langford(11:10 - 11:45)

Why is Arabia in Need for a Rheumatology Nurse

Khalid Alnaqbi& Nafaja Salem

Postgraduate Medical Training in the UK for International Medical

GraduatesAsad Zoma

12:10 - 13:30 PRAYER FOLLOWED BY LUNCH

Sessions

Vasculitis (II)- To Familiarize with Highlight

Advancements of Vasculitis Research in Asia Pacific

Region, Co-Sponsored by Vasculitis SIG

The Great Debate Pediatric Rheumatology II Oral Abstract Presentations

13:30 - 13:55

ANCA Associated Vasculitides- Japanese

Experience in Comparison With Other Ethnicities

Yoshihiro ArimuraThe Great APLAR Debate

Waleed AlShehhi & John Cush

Ultrasound in Pediatric Rheumatology Clinics:

The Clinician’s ToolAlice Leahy


The Clinical Characteristics of Chinese

Vasculitis Patients Xinping Tian

Auto-Inflamatory Disordersin Children

Basil Fathalla

14:20 - 14:45Vascular Involvement in

Behcet’s SyndromeJuma AlKaabi

Adult vs Childhood onsetSystemic Lupus Erythematosus

Reem Abdwani

14:45 - 15:15 CLOSING CEREMONY

Friday, 20October, 2017


PROGRAM AT A GLANCE

Dubai Room A (Level C1)07:30 - 08:30 Meet the Expert 3: Management of Lupus Nephritis - Abdullatif Al-Arfaj

21

Location of Rooms: DWTC C1 Floor

APLAR MEMBERS FORUM& MEET THE EXPERT SCHEDULE




Thursday, 19October, 2017

Dubai Room D14:00 - 15:45 APLAR Members Forum

Dubai Room A

07:30 - 08:30Meet the Expert 1

Polymyalgia Rheumatica John Axford

Dubai Room A


Immunology SessionMasataka Kawana

Dubai Room F17:55 - 18:55 Young Rheumatologists

Dubai Room C & D17:55 - 18:55 SIG Group Meeting

Dubai Room A


Management of Lupus NephritisAbdullatif Al-Arfaj

Dubai Room C09:00 - 17:00 APLAR Review Course

22

PRE-CONGRESS MUSCULOSKELETAL ULTRASOUND WORKSHOP - SHEIKH RASHED HALL A (GF)

Faculty:• Anwar Samhari Arshad • Ahmed Abogamal • Ghita Harifi08:30 - 09:00 Registration09:00 - 09:10 Opening Remarks - Anwar Arshad / Waleed AlShehhi

Chairpersons: Ghita Harifi / Anwar Arshad09:10 - 09:30 US in Rheumatology - Ahmed Abogamal09:30 - 09:50 Sonographic Patterns of Musculoskeletal Tissues and Correlations With Anatomy and Histology - Peter Balint09:50 - 10:10 Sonographic Semiology (Tendinosis, Tenosynovitis, Partial and Complete Tendon Tear, Entesopathy, Bursitis,

Calcifications, Articular Cartilage Lesions, Cortical Abnormalities and Joint Synovitis) - Esperanza Naredo10:10 - 10:30 Coffee Break10:30 - 10:50 Knobology / Machine Setting and Optimisation - David Kane10:50 - 11:10 Artifacts and Misinterpretation in MSUS - Ghita Harifi11:10 - 11:40 US of the Hip. Normal Findings and Basic US Pathology - Lecture / Live Demo: Peter Balint11:40 - 13:00 Workshop 1: Sonoanatomy and Stardard Scans of the Hip. How to Perform and US Examination in Healthy

Subjects and Obtain US Images.13:00 - 14:00 Lunch Break

Chairpersons: Gavin Lee / Ghita Harifi14:00 - 14:30 US of the Knee. Normal Findings and Basic US Pathology - Lecture / Live Demo: Zunaid Karim14:30 - 16:00 Workshop 2: Sonoanatomy and Standard Scans of the Knee. How to Perform an US Examinations in

Healthy Subjects and Obtain US Images.16:00 - 16:15 Coffee Break16:15 - 16:45 US of the Ankle and Foot. Normal Findings and Basic US Pathology - Lecture / Live Demo: Ingrid Moller16:45 - 18:15 Workshop 3: Sonoanatomy and Standard Scans of the Ankle and Foot. How to Perform an US Examination

in Healthy Subjects and Obtain US Images

Chairpersons: Gavin Lee / Ghita Harifi08:30 - 09:00 US of the Shoulder. Normal Findings and Basic US Pathology - Lecture / Live Demo: Ahmed Abogamal09:00 - 10:30 Workshop 4: Sonoanatomy and Standard Scans of the Shoulder. How to Perform an US Examination in

Healthy Subjects and Obtain US Images.10:30 - 10:45 Coffee Break10:45 - 11:15 US of the Elbow. Normal Findings and Basic US Pathology - Lecture / Live Demo: David Kane

Chairpersons: Gavin Lee / Ahmad Abogamal11:15 - 12:45 Workshop 5: Sonoanatomy and Standard Scans of the Elbow. How to Perform an US Examination in

Healthy Subjects and Obtain US Images.12:45 - 13:45 Lunch Break13:45 - 14:15 US of the Hand and Wrist. Normal Findings and Basic US Pathology - Lecture / Live Demo: Esperanza Naredo14:15 - 15:45 Workshop 6: Sonoanatomy and Standard Scans of the Hand and Wrist. How to Perform an US

Examinations in Healthy Subjects and Obtain US Images.15:45 - 16:00 Closing / Coffee - Anwar Arshad and All Fascilitators

MUSCULOSKELETALULTRASOUND WORKSHOP

Monday, 16 October, 2017

Tuesday, 17 October, 2017

23

APLAR REVIEW COURSE - DUBAI ROOM C (C1 FLOOR)

09:00 - 09:40Rheumatoid ArthritisUpdates in Rheumatoid Arthritis Treatment Tsutomu Takeuchi

09:40 - 10:20Ankylosing SpondyloarthritsUpdate In SpondyloarthritsJames Cheng-Chung Wei

10:20 - 10:50 Coffee Break

10:50 - 11:30Systemic Lupus ErythematosusAn Update on the Diagnosis and Management of Neuropsychiatric LupusAnselm Mak

11:30 - 12:10OsteoarthritisOsteoarthritis and ExerciseAli Jawad

12:10 - 13:10 Lunch Break

13:10 - 13:50GeneticsGenetics in Rheumatology Yukinori Okada

13:50 - 14:30VasculitisApproach to Vasculitic DisordersRamnath Misra


15:00 - 15:40Crystal Induced ArthritisOverview and Advances in Crystal ArthropathiesEdward Roddy

15:40 - 16:20Systemic SclerosisOverview of Systemic SclerosisYossra Suliman

APLAR REVIEW COURSE


24

PRE-CONGRESS MUSCULOSKELETAL MRI WORKSHOP - SHEIKH RASHED HALL B (GF)

Course Director: Bhavna Khan

Faculty:• Mikkel Østergaard • Paul Bird • Bhavna Khan • Ashish Mathew

08:30 - 09:00 Registration

09:00 - 09:15 Opening Remarks and Introduction - Bhavna Khan

MRI Sacroiliac Joints: Mikkel Østergaard

09:15 - 09:30 SI joints - MR Anatomy and Normal Appearances

09:30 - 09:45 MRI SI Joints - Abnormal Appearances and Identification of Pathology

09:45 - 10:15 MRI SI Joints - Spondyloarthritis


MRI Spine: Paul Bird

10:30 - 10:45 MRI Spine - Anatomic Considerations

10:45 - 11:00 MRI Spine - Normal Appearance and X Ray Correlation

11:00 - 11:30 MRI Abnormalities in Spine / Identification of Pathology / Pitfalls

Interactive Session 1: Mikkel Østergaard - Paul Bird

11:30 - 12:30

MRI Spine and SI Joints: (Interactive Voting smart Phone Scoring)Identifying SequencesIdentifying Normal Structures Spine and SI JointsSelected Pathology and Differential Diagnoses


Interactive Session 2: Mikkel Østergaard - Paul Bird - Ashish Mathew

14:00 - 15:30MRI Sacroiliac Joints and Spine: (Basic Pathology - Interactive Voting smart Phone Scoring)Participants will review approximately 10 SIJ Cases and 10 Spine Cases. Each participant will undertake interactive voting machine/smart phone scoring. Scores will be reviewed and each case discussed in detail.


Interactive Session 3: Mikkel Østergaard - Paul Bird - Bhavna Khan

15:45 - 17:15 MRI Spine and SI Joints (Advanced Pathology - Interactive Voting smart Phone Scoring)

17:15 - 17:30 Feedback and End of Day 1

MUSCULOSKELETALMRI WORKSHOP

Monday, 16October, 2017

25

PRE-CONGRESS MUSCULOSKELETAL MRI WORKSHOP - SHEIKH RASHED HALL B (GF)

Course Director: Bhavna Khan

Faculty:• Mikkel Østergaard • Paul Bird • Bhavna Khan • Ashish Mathew

08:00 - 08:15 Introduction - Bhavna Khan

MRI Peripheral Joints: Paul Bird - Ashish Mathew

08:15 - 08:30 MCP / MTP Joints and Wrist - MR Anatomy and Normal Appearances

08:30 - 08:45 MCP / MTP Joints and Wrist - Identification of Pathology

08:45 - 09:15 Basic Pathology and Pitfalls - RA / PsA: Synovitis, Erosions, Osteitis and Tenosynovitis



09:30 - 11:30

MRI Scan of Wrist’s, Hands and Feet (Interactive Voting Smart Phone Scoring)Identifying SequencesIdentifying Normal Structures - MCP Joints / MTP Joints / WristIdentifying Basic Pathology - MCP Joints / MTP joints / WristDifferential Diagnoses


Interactive Session 2: Mikkel Østergaard - Paul Bird - Ashish Mathew

13:00 - 14:15MRI Wrists, Hands and Feet: (Basic Pathology - Interactive Voting Smart Phone Scoring)Participants will review approximately10 wrists, hands and feet MRI cases. Each participant will undertake interac-tive voting machine/smart phone scoring. Scores will be reviewed and each case discussed in detail.



14:30 - 15:15MRI Wrists, Hands and Feet: (Advance Pathology - Interactive Voting Smart Phone Scoring)Participants will review approximately 10 wrists, hands and feet MRI cases. Each participant will undertake interac-tive voting machine/smart phone scoring. Scores will be reviewed and each case discussed in detail.

15:15 - 15:30 Feedback and End of Day 2


MUSCULOSKELETALMRI WORKSHOP

References: 1. Jung SM, Kim KW, Yang CW, Park SH, Ju JH. Cytokine-mediated bone destruction in rheumatoid arthritis. J Immunol Res. 2014;2014:263625. 2. Dayer JM, Choy E. Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor. Rheumatology (Oxford). 2010;49(1):15-24. 3. Choy E. Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford). 2012;51(suppl 5):v3-v11. 4. Goldring SR. Inflammatory signaling induced bone loss. Bone. 2015;80:143-149. 5. Goldring SR. Periarticular bone changes in rheumatoid arthritis: pathophysiological implications and clinical utility. Ann Rheum Dis. 2009;68(3):297-299. 6. Hoff M, Haugeberg G, Odegård S, et al. Cortical hand bone loss a�er 1 year in early rheumatoid arthritis predicts radiographic hand joint damage at 5-year and 10-year follow-up. Ann Rheum Dis. 2009;68(3):324-329. 7. Stewart A, Mackenzie LM, Black AJ, Reid DM. Predicting erosive disease in rheumatoid arthritis. A longitudinal study of changes in bone density using digital X-ray radiogrammetry: a pilot study. Rheumatology (Oxford). 2004;43(12):1561-1564. 8. Sche¢ G, Gravallese E. Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment. Nat Rev Rheumatol. 2012;8(11):656-664. 9. Van der Heijde DM. Joint erosions and patients with early rheumatoid arthritis. Br J Rheumatol. 1995;35(suppl 2):74-78. 10. van Staa TP, Geusens P, Bijlsma JW, Leu¤ens HG, Cooper C. Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54(10):3104-3112. 11. Yoshitake F, Itoh S, Narita H, Ishihara K, Ebisu S. Interleukin-6 directly inhibits osteoclast differentiation by suppressing receptor activator of NF-kappaB signaling pathways. J Biol Chem. 2008;283(17):11535-11540.

©2017 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. 09/2017 SAGLB.IMM.17.08.1068e

Clinical consequences of bone resorption in patients with RA

In RA, homeostasis in bone is disrupted, resulting in uncoordinated osteoclast formation and a skewing toward bone resorption.1-3

THE ROLE OF IL-6 IN BONE RESORPTION

RHEUMATOID ARTHRITIS (RA) AND

Adapted from Choy 2012.

Distinct pa�erns of bone remodeling are found in patients with RA4:

Periarticular osteopenia refers to reduced bone mineral density (BMD) at the interface of bone and cartilage in joints such as the knee, wrist, and small joints of the hands and feet. It is predictive of subsequent development of joint erosions of the hand.4-7

Focal joint erosions are found at sites where the inflamed synovial lining or pannus contacts bone surface. Bone erosion occurs in more than half of patients within the first 2 years of disease onset.4,8,9

Systemic osteoporosis refers to the systemic reduced BMD associated with RA. Patients with RA who have reduced BMD are at an increased risk of fracture.4,10

Reduced BMD contributes to the higher risk of fracture associated with RA.4 In one study, more than 30,000 patients with RA from the British General Practice Research Database had a 1.5-fold increase in clinical fracture risk compared with control patients.10

Interleukin-6 (IL-6) and other pro-inflammatory cytokines are triggers of osteoclast differentiation and bone resorption1

IL-6, IL-1, IL-17, and tumor necrosis factor-α (TNF-α) either directly trigger osteoclast differentiation or support it indirectly by increasing the expression of receptor activator of nuclear factor kappa-B ligand (RANKL).1

Effects of elevated IL-6 signaling on bone metabolism in RA

Under steady-state conditions, IL-6 contributes to homeostatic regulation of osteoblast and osteoclast function, thereby preventing bone resorption.1 However, under inflammatory conditions such as RA, increased presence of the soluble IL-6 receptor (sIL-6R) allows IL-6 to induce the expression of RANKL on osteoblasts and fibroblast-like synoviocytes (FLS cells), leading to increased osteoclast differentiation and, ultimately, greater bone resorption.11

Elevated IL-6 signaling and the subsequent increase in bone resorption may lead to bone loss and joint destruction in patients with RA2,11

SAGLB.IMM.17.08.1068e_16909_R01_Advert3_2017.indd All Pages 9/20/17 4:29 PM

� Superior reductions in SLE disease activity.2,‡

� A 39% relative risk reduction of severe flare.2,§

� A reduction in corticosteroid dose in patients on ≥7.5 mg/day at baseline.2,¶

� An improvement in fatigue scores as early as Week 8.2,¥

� Similar adverse event profile to standard therapy alone.1

1. Benlyta Local Prescribing Information. 2. van Vollenhoven RF et al. Ann Rheum Dis. 2012; 71: 1343-1349. *Defi ned by low complement and positive anti-dsDNA at baseline. †BLISS-52 and BLISS-76 pooled data. ‡51.5% SRI response rate vs. 31.7% with standard therapy + placebo (p<0.001). §HR (95% CI) 0.61 (0.44, 0.85); p=0.004 vs. placebo + standard therapy. ¶ 7.5 mg/day reduction in 24.6% vs. 15.0% with standard therapy + placebo (p=0.035). ¥FACIT-Fatigue score improvement from baseline at week 52 (least-squares mean) 4.07 vs. 1.80 with placebo + standard therapy (p=0.004).

Abbreviated Prescribing Information for use in UAE, Kuwait & Oman based on BENLYSTA prescribing Information (GDS11IPI09). It is prepared to meet the requirements of the GSK International Pharmaceutical Promotional and Marketing Policy. BENLYSTA is a recombinant, fully human, IgG1� monoclonal antibody. It’s a sterile lyophilised powder in a single use 120 and 400 mg vials. Indications: BENLYSTA is indicated for reducing disease activity in adult patients with active autoantibody positive systemic lupus erythematosus (SLE) who are receiving standard therapy. Dosage and Administration: The recommended dosage regimen for adult patients (18 years old and above) is 10 mg/kg on Days 0, 14 and 28, and at 4-week intervals thereafter. BENLYSTA is administered intravenously by infusion over a 1-hour period, and must be reconstituted and diluted prior to administration. It should be administered by a healthcare professional prepared to treat hypersensitivity reactions including anaphylaxis. Patients should be monitored during and for an appropriate period of time after administration of BENLYSTA. The infusion must be discontinued immediately if the patient experiences a potentially life-threatening adverse reaction. Special Populations: Elderly: Limited data present, children: No data available, Renal and hepatic Impairment: No formal studies of BENLYSTA have been performed in patients with renal & hepatic impairment. Contraindications: BENLYSTA is contraindicated in patients who have demonstrated anaphylaxis to BENLYSTA. Warnings and Precautions: Caution should be exercised if BENLYSTA is co-administered with other B cell targeted therapy or cyclophosphamide because it has not been studied in combination with other B cell targeted therapy or intravenous cyclophosphamide. Administration of BENLYSTA may result in infusion and hypersensitivity reactions, which can be severe, and can be fatal. As with other immunomodulating agents, the mechanism of action of BENLYSTA may increase the potential risk for the development of infections. Progressive multifocal leukoencephalopathy (PML) resulting in neurological defi cits, including fatal cases, has been reported in SLE patients

receiving immunosuppressant pharmacotherapy, including BENLYSTA. Malignancy: As with other immunomodulating agents, the mechanism of action of BENLYSTA may increase the potential risk for the development of malignancies. Immunisation: Live vaccines should not be given for 30 days before, or concurrently with BENLYSTA as clinical safety has not been established. Fertility: There are no data on the effects of BENLYSTA on human fertility. Pregnancy: There are limited data on the use of BENLYSTA in pregnant women and it should be used during pregnancy only if the potential benefi t to the mother justifi es the potential risk to the foetus. Women of childbearing potential should take precautions to avoid pregnancy while being treated with BENLYSTA. Lactation: There are no data regarding the excretion of belimumab in human milk, or systemic absorption of belimumab after ingestion. However, belimumab was excreted into the milk of cynomolgous monkeys. There have been no studies to investigate the effect of BENLYSTA on driving performance or the ability to operate machinery. Adverse Reactions: Very common (≥ 1 in 10): Non-opportunistic infections. Common (≥ 1 in 100 and < 1 in 10): Hypersensitivity reaction, Pyrexia and Infusion-related reaction. Uncommon (≥ 1 in 1,000 and <1 in 100): Anaphylactic reaction, Angioedema, Rash and Urticaria. Overdose: There is no clinical experience with overdosage of BENLYSTA. Drug interactions: No drug interaction studies have been conducted with BENLYSTA. Concomitant use of mycophenolate mofetil, azathioprine, methotrexate and hydroxychloroquine did not substantially infl uence belimumab pharmacokinetics. Neither did a wide range of other co-medications (non-steroidal anti-infl ammatory medications, aspirin, and HMG-CoA reductase inhibitors), Steroids and ACE inhibitors resulted in a statistically signifi cant increase of systemic clearance in the population pharmacokinetic analysis. However, these effects were not clinically meaningful. Incompatibilities: BENLYSTA is not compatible with 5% dextrose. BENLYSTA prescribing Information Version number: GDS11IPI09, Date of issue: 09 December 2013.

For full prescribing information, please refer to the data sheet or contact GlaxoSmithKline: P.O. Box 50199, Dubai, United Arab Emirates.

Telephone: Bahrain +973 1 7377053, Kuwait +965 2 2053233, Oman +968 2 4571317, Qatar +974 44065455, UAE +971 4 4037100, KSA +966 12 653 6666.

To report Product Complaint/s or Adverse Event/s associated with the use of GSK product/s, please contact us via [email protected]

GCC/BEL/0013/17a Date of Preparation September 2017

Cutterguide: N/A Printing Process: OffsetGD: VV27293

Size: A4 (210 x 297) mm, Pages: 1 Colors: C M Y K (4 Color)Native File: Indesign CS5 Windows Generated in: Acrobat Distiller XI

� Could it be time to consider adding BENLYSTA instead of more of the same?

� Adding BENLYSTA provided signifi cant benefi ts vs. standard therapy alone in patients with persistent disease activity.1,2,*,†

Benlysta_Advert_GSKDC-PT-ARE-2017-1908_D3.indd 1 9/11/2017 3:30:34 PM

29


Sheikh Rashid Hall F16:00 - 17:00 Non-Infectious Uveitis: Beyond the Joints - A Vision for all Maximizing

Treatment Outcomes at all Ages Through Optimal Multidisciplinary Collaborations Symposium Sponsored by AbbvieChairperson: Waleed AlShehhi

16:00 - 16:05 Welcome and introduction How do we Create a Vision for All?

Waleed AIShehhi

16:05 - 16:20 Keeping an eye on our pediatric patients Avinash Gurbaxani16:20 - 16:35 Establishing the Evidence Base for the Management of Non-Infectious

Uveitis: The Importance of Co-Management Muhammad Haroon

16:35 - 16:50 Near and Distant Vision: Treatment Goals in Adult Non-Infectious Uveitis

Piergiorgio Neri

16:50 - 17:00 Roundtable Discussion:Optimizing the Care of Rheumatologic Patients with Ocular Manifestations

All

Sheikh Rashid Hall C & D16:00 - 17:00 Symposium Sponsored by Janssen

16:00 - 17:00 Adherence, Persistence and Impact on Patient’s Outcomes Paul Emery

17:00 - 18:00 Opening Ceremony Sheikh Rashid Hall F

18:00 Welcome Reception Sheikh Rashid Hall E

20:30 PRESIDENTIAL DINNER by Invitation Only

DETAILED SCIENTIFIC PROGRAM

30


Sheikh Rashid Hall F08:30 - 09:15 Combined Plenary Session I

08:30 - 09:15 Management of Inflammatory Joint Diseases Tore Kvien

09:15 - 10:00 Combined Plenary Session II

09:15 - 10:00 Evolving Trends in of RA TreatmentsWaleed AlShehhiPeter NashEduardo Mysler


10:30 - 11:45 Symposium Sponsored by Lilly

10:30 - 10:35 Welcome and Introduction Jamal Al-Saleh

10:35 - 11:05Review of JAK Inhibitors, Overview of What the New Options Mean for Treatment Algorithms in the Context of EULAR Recommendations and ACR Guidelines

Kevin Pile

11:05 - 11:35 Baricitinib: Overview of Efficacy Paul Emery11:35 - 11:45 Questions and Discussion Jamal Al-Saleh

11:45 - 13:00 Spondyloarthritis (I), Co-Sponsored by SpA SIGChairpersons: Jieruo Gu, Nazrul Islam

11:45 - 12:10 Mechanisms - Based Treatment of SpA - Lessons from Pathophysiology for Modern Treatment of SpA

Georg Schett

12:10 - 12:35 Cardiovascular Risk Screening in Spondyloarthritis:What Should We Do in Clinical Practice?

Lai-Shan Tam

12:35 - 13:00 Non-Radiographic Axial Spondyloarthritis, Concept or Reality? James Cheng-Chung Wei

13:00 - 14:30 Deep Dive into SpA : The Way to an Integrative ApproachLunch Symposium Sponsored by Abbvie

Chairperson: Khuloud Saleh13:20 - 13:25 SpA: The Multi-Faceted Disease Khuloud Saleh13:25 - 13:40 Gut Inflammation in SpA: Prevalence, Significance and Treatment

ImplicationsTimothy R. Orchard

13:40 - 13:55 Evolving Diagnostic Criteria and Management of Anterior Uveitis in the Context of SpA

Piergiorgio Neri

13:55 - 14:10 Diagnosis and Treatment Challenges in PsA: The Dermatology View Diamant Thaçi14:10 - 14:20 How Could Integrative Management be Accomplished in Patients with SpA Khuloud Saleh14:20 - 14:30 Panel Discussion All


31


14:30 - 15:45 SclerodermaChairpersons: Lisa Christopher-Stine, Eun Young Lee

14:30 - 14:55 Immunogenetics of Scleroderma Masataka Kuwana

14:55 - 15:20 Pulmornary Hypertension in Scleroderma Christopher Denton

15:20 - 15:45 The Utility of Capilloroscopy for Early Diagnosis and Management of Scleroderma

Maurizio Cutolo


16:15 - 17:55 Myositis & Granuloma Chairpersons: Sharad Lakhanpal, Fereydoun Davatchi

16:15 - 16:40 Difficult Myositis: A Case-Based Approach Lisa Christopher-Stine

16:40 - 17:05 Antisynthetase Syndrome, Beyond Inflammatory Myositis Hussein Halabi

17:05 - 17:30 IgG4 Related Diseases Salwa Al-Cheikh

17:30 - 17:55 Musculoskeletal Features of Sarcoidosis Ali Jawad



32


Sheikh Rashid Hall C & D

07:30 - 08:30 Genetic SIG / Business Meeting

08:30 - 09:15 Combined Plenary Session I Sheikh Rashid Hall F

08:30 - 09:15 Management of Inflammatory Joint Diseases Tore Kvien

09:15 - 10:00 Combined Plenary Session II Sheikh Rashid Hall F

09:15 - 10:00 Evolving Trends in of RA TreatmentsWaleed AlShehhi Peter NashEduardo Mysler


10:30 - 11:45 Symposium Sponsored by Pfizer

10:30 - 10:35 Welcome and Introduction Waleed AlShehhi10:35 - 11:15 Treatment Strategies for the Complex Manifestations of Axial Spondyloarthritis Bassel El-Zorkany11:15 - 11:25 Optimizing PSA Care in Clinical Practice Eduardo Mysler11:25 - 11:45 Rising to the Challenge; Patient Case Study Eduardo Mysler

11:45 - 13:00 Connective Tissue DiseasesChairpersons: Munther Khamashta, Sandra Navarra

11:45 - 12:10 Neuro - Immunologic Axis in Sjogren’s Syndrome Sapan Pandya12:10 - 12:35 SLE in Pregnancy Monika Østensen

12:35 - 13:00 Safety of Therapeutic Agents in pregnant Women With Autoimmune Rheumatic Diseases (ARDs)

Bhavna Khan

13:00 - 14:30 Rheumatoid Arthritis: Every Aspect Counts Lunch Symposium Sponsored by NewBridge Pharmaceuticals Chairperson: Waleed AlShehhi

13:20 - 13:25 Welcome and Introduction Waleed AlShehhi13:25 - 13:55 Rheumatoid Arthritis: Every Aspect Counts Peter Taylor13:55 - 14:25 Meeting Patient’s Needs in PsA Peter Nash14:25 - 14:30 Summary and Closing Waleed AlShehhi

14:30 - 15:45 SLE - Improving The Outcome of Systemic Lupus Erythematosus, Co-Sponsored by SLE SIGChairpersons: Sapan Pandya, Alhussain Asiri

14:30 - 14:55 Lupus & Musculoskeletal System Sandra Navarra14:55 - 15:20 Treatment of Lupus Nephritis - Current Status and Future Directions Daniel TM Chan15:20 - 15:45 Long-term Outcome of SLE in China - What CSTAR Told us? Mengtao Li


16:15 - 17:55 Connective Tissue Diseases IIChairpersons: Monika Østensen, Daniel TM Chan

16:15 - 16:40 The Use and Abuse of Autoantibodies in Clinical Practice Munther Khamashta16:40 - 17:05 Infection Associated Vasculitic Aman Sharma17:05 - 17:30 Management of Rare and Difficult Infections in the Lupus Patient C. Balakrishnan17:30 - 17:55 Sjogren’s Syndrom Updates Alhussain Asiri



33


Sheikh Rashid Hall A07:30 - 08:30 SLE SIG Business Meeting

08:30 - 09:15 Combined Plenary Session I Sheikh Rashid Hall F08:30 - 09:15 Management of Inflammatory Joint Diseases Tore Kvien




11:45 - 13:00 Rheumatoid ArthritisChairpersons: Suad Hannawi - Rammath Misra

11:45 - 12:10 The LERACS Study:Patient Preferences Regarding Rheumatoid Arthritis Treatments

Fouad Fayad

12:10 - 12:35 Towards Cure for RA - Optimizing Therapy in Inflammatory Arthritis Yasser El Miedany

12:35 - 13:00 Kuwait Registry for Rheumatic Diseases on the Wheel of Success Adeeba Al-Herz

14:30 - 15:45 Psoriatic Arthritis & Related DisordersChairpersons: Sukhbeer Uppal - C. Balakrishnan

14:30 - 14:55 An Early Diagnosis of Psoriatic Arthritis Mitsumasa Kishimoto

14:55 - 15:20 Approach to Vasculitic Disorders Ramnath Misra

15:20 - 15:45 Gout: Integrating Myths, Fact and Science Rohini Handa


16:15 - 18:55 OA - Osteoarthritis: Epidemiology and Basic Research in Asia-Pacific Region, Co-Sponsored by OA SIGChairpersons: Syed Atiqul Haq, Mongkol Vatanasuk

16:15 - 16:40 The Role of Inflammation in Osteoarthritis Katy Leung Ying Ying

16:40 - 17:05 Epidemiology Of the Locomotive Syndrome: The Research on Osteoarthritis/Osteoporosis Against Disability Study

Noriko Yoshimura

17:05 - 17:30 OA in Asia Pacific- A WHO COPCORD Perspective Arvind Chopra

17:30 - 17:55 Osteoarthritis Disease Outcomes Ester Gonzales-Penserga

17:55 - 18:55 SpA SIG Buisness Meeting



34


Sheikh Rashid Hall B07:30 - 08:30 RA SIG Business Meeting

08:30 - 09:15 Combined Plenary Session I Sheikh Rashid Hall F08:30 - 09:15 Management of Inflammatory Joint Diseases Tore Kvien




11:45 - 13:00 Oral Abstract Presentations PresentersChairpersons: Noriko Yoshimura, Ali Jawad

11:45 - 11:55Impact Of Fibromyalgia On Health Associated Quality Of Life In Patients with Psoriatic Arthritis A. SHARMA, H. KANCHARLA, S. MISHRA, S. DOGRA

Aman Sharma

11:55 - 12:05Serum and synovial fluid levels of Resistin as biomarker for primary knee osteoarthritis flare upsM. GAMAL, H. BASSIOUNI, M. ELDAHAN, K. ZAKY, A. ALI

Mohammed Gamal Abdel Rahman

12:05 - 12:15

Comparative efficacy and safety of baricitinib 2 mg and 4 mg in patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trialsY. H. LEE, Y. H. SEO, G. G. SONG

Young Ho Lee

12:15 - 12:25Diagnostic utility of salivary gland ultrasound in primary Sjögren syndrome based on the 2016 ACR/EULAR classification criteriaY. GENG, B. LI, X. DENG, L. JI, X. ZHANG, Z.-L. ZHANG

Yan Geng

12:25 - 12:35

Effect of achieving sustained SDAI remission on erosion repair in patients with early RA: a prospective HR-pQCT studyJ. YUE, J. F. GRIFFITH, J. XU, F. XIAO, L. SHI, D. WANG, P. WONG, E. K.LI, M. LI, T. K. LI, T. Y. ZHU, L. QIN, L.-S. TAM

Jiang YUE

12:35 - 12:45Serum KL-6 level reflects severity of interstitial lung disease associated with connective tissue diseaseJ. S. LEE, E. Y. LEE, J. K. PARK, E. B. LEE, Y. W. SONG

Jeong Seok Lee

12:45 - 12:55

Pathogenetic links between localised and systemic sclerosis: a translational study of keloidal morphea in sclerodermaE. DERRETT-SMITH, N. GAK, S. NIHTYANOVA, V. ONG, V.SWALE, C. ORTEU, C. P. DENTON

Emma ClaireDerrett-Smith

APLAR BEST ABSTRACTS AWARDS


35


14:30 - 15:45 Oral Abstract Presentations PresentersChairpersons: James Cheng-Chung Wei, Katy Leung Ying Ying

14:30 - 14:40

Secukinumab leads to 2-year sustained minimal disease activity in patients with active psoriatic arthritis: Results of the Phase-3 FUTURE-2 StudyP Nash, PJ Mease, LC Coates, L Gossec, B Kirkham, L Rasouliyan, C Gaillez, L Prico, S Jugl, KK Gandhi

Peter Nash

14:40 - 14:50

Serum And Urinary Interleukin-17 (Il-17) As Biomarkers Of Disease Activity In Systemic Lupus Erythematosus (Sle)S. Sazliyana Shaharir, Fariz Nordin, Asrul A Wahab, Ruslinda M, Sakthiswary R, Mohd Shahrir MS, Halim AG, Shamsul A Shah

Syahrul Sazliyana Shaharir

14:50 - 15:00

Peptidylarginine deiminase 4 deficiency ameliorated imiquimod-induced lupus model miceN. HANATA, H. SHODA, T. KOMAI, T. OKAMURA, A. SUZUKI, K.YAMAMOTO, K. FUJIO

Norio Hanata

15:00 - 15:10

Association of serum interleukin-6,TNF receptor and interleukin-17 levels with disease activity in Japanese patients with SAPHO syndromeM. TAMURA, K. MATSUI, K. AZUMA, K. TSUBOI, C. OGITA, M. TANI, T.YOSHIKA-WA, T. HINO, A. NISHIOKA, M. MORIMOTO, N. AZUMA, M.KITANO, H. SANO

Masao Tamura

15:10 - 15:20

Sarilumab as Monotherapy or Combination Therapy in Patients With RA and Intolerance or Inadequate Response to Methotrexate M. C. GENOVESE, H. VAN HOOGSTRATEN, E. K. MANGAN, S.JAYAWARDENA,G. R. BURMESTER

Hubert van Hoogstraten

15:20 - 15:30

Precision medicine using different biological DMARDs based on charac-teristic phenotypes of peripheral T helper cells in patients with psoriatic arthritisI. MIYAGAWA, S. NAKAYAMADA, K. NAKANO, S. KUBO, S. IWATA, Y.MIYAZAKI, M. YOSHIKAWA, H. YOSHINARI, Y. TANAKA

Ippei Miyagawa

15:30 - 15:40The Association Of Serum Pyridinoline With Radiographic Joint Erosions In Rheumatoid ArthritisS. RAJALINGHAM, N. H. A. M. MATARDIAH, R. SRIDHARAN

Sakthiswary Rajalingham

APLAR BEST ABSTRACTS AWARDS15:45 - 16:15 COFFEE BREAK & POSTER VIEWING

16:15 - 18:55 Interstitial Lung Disease in Rheumatic DiseasesChairpersons: Maurizio Cutolo, Masataka Kawana

16:15 - 16:40 Interstitial Lung Disease in Scleroderma Christopher Denton

16:40 - 17:05 Interstitial Lung Disease in RA Eun Young Lee

17:05 - 17:30 Computer Assisted Diagnostic of ILD Grace Kim

17:30 - 17:55 Lung in Lupus Ala’ AlHeresh

17:55 - 18:55 OA SIG Business Meeting



36

Sheikh Rashid Hall F08:30 - 09:15 Combined Plenary Session I Sheikh Rashid Hall F08:30 - 09:15 Why Should Rheumatologists Know Genetics? Kazuhiko Yamamoto

09:15 - 10:00 Combined Plenary Session II Sheikh Rashid Hall F09:15 - 10:00 Update on Immuno-Pathogenesis of Axial SpondyloArthritis Bassel El-Zorkany


10:30 - 11:45 Symposium Sponsored by Pfizer

10:30 - 10:35 Welcome and Introduction Jamal Al-Saleh10:35 - 10:45 TNF Inhibitors in RA = Always & Again Peter Nash10:45 - 11:15 JAK Inhibition: Deep Dive Into Efficacy and Safety Data in RA Peter Nash11:15 - 11:45 Managing Cost Considerations in Patients with RA Eduardo Mysler

11:45 - 13:00 Arthritis, Practical AspectsChairpersons: Mark Goloviznin, Yasser El Miedany

11:45 - 12:10 Novel Bio Products and Post Bio Strategy Against Rheumatic Disease Kusuki Nishioka

12:10 - 12:35 Kuwait Consensus on Vaccine Use in People with Inflammatory Rheumatic Disease

Ahmad ALEnizi

12:35 - 13:00 Inflammation Links Cardiovascular Risk Factors to Cardiovascular Disease in Rheumatoid Arthritis

Suad Hannawi

13:00 - 14:30 Lunch Symposium Sponsored by Novartis

13:00 - 14:30 IL-17A a paradigm Shift in the management of SpAPeter NashPhilip HelliwelMikkel Østergaard

14:30 - 15:45 EULAR SymposiumChairpersons: Sharad Lakhanpal, Kazuhiko Yamamoto

14:30 - 14:55 Psoriatic Arthritis: Current Treatments Towards New Strategies? Iain McInnes

14:55 - 15:20 Systemic Sclerosis (Scleroderma) New EULAR Guidelines and Treatment Recommendations

Maurizio Cutolo

15:20 - 15:45 EULAR Guidelines on Treatment of Rheumatoid Arthritis Johannes W.J. Bijlsma


16:15 - 17:55 COPCORD & Epidemiological Aspects in RheumatologyChairpersons: Debashish Danda, Adeeba Al-Herz

16:15 - 16:40 APLAR-COPCORD: The Past, Present and Future Syed Atiqul Haq

16:40 - 17:05 Does Delay Matter in Early Arthritis? Jamal Al-Saleh

17:05 - 17:30 Malignancy and Rheumatic Diseases Gamal Ibrahim

17:30 - 17:55 Central Nervous System Manifestations of Neuropsychiatric Lupus:The Pakistani Experience

Nighat Mir Ahmad




37

Sheikh Rashid Hall C & D08:30 - 09:15 Combined Plenary Session I Sheikh Rashid Hall F08:30 - 09:15 Why Should Rheumatologists Know Genetics? Kazuhiko Yamamoto



10:30 - 11:45 Optimizing Long-Term Therapy: How Can We Deliver The Outcomes Patients Need?Symposium Sponsored by AbbvieChairperson: Hussein Halabi

10:30 - 10:45 Inflammatory Arthritis or Early RA:One and the Same? How do we Act Earlier?

Hussein Halabi

10:45 - 11:00 Taking the Patient From the Target to the Goal: How do we Implement the Most Effective Approach?

Daniel Aletaha

11:00 - 11:15 Delivering the Long Term Treatment Aspirations of the Patient and the Clinician: What is the Latest Data?

Andrew Östör

11:15 - 11:35 In a Changing World, How do you Select the Right Therapy for the Long Term Benefit of the Patient?

Iain McInnes

11:35 - 11:45 Panel discussion All

11:45 - 13:00 Vaculitis / Intravascular CoagulationChairpersons: Carol Langford, John Axford

11:45 - 12:10 Clinical Pictures of Behcet’s Disease in Different Parts of the World Fereydoun Davatchi

12:10 - 12:35 Catastrophic AntiphosphoLipids Syndrome Munther Khamashta

12:35 - 13:00 Diagnosis and Management of Takayasu’s Arteritis - a South Asian Perspective

Debashish Danda

13:00 - 14:30 Lunch Symposium Sponsored by Lilly

13:00 - 13:05 Welcome and Introduction Jamal Al-Saleh13:03 - 13:35 Baricitinib: Overview of Effects on Joint Structure Kevin Pile 13:35 - 14:05 Baricitinib: Safety Overview Paul Emery14:05 - 14:30 Questions and Discussion Jamal Al-Saleh

14:30 - 15:45 Osteoperosis & Bone HealthChairpersons: Mustafa Al Izzi, Jamal Al-Saleh

14:30 - 14:55 Osteoporosis Management Today and in the Future Ian Reid

14:55 - 15:20 Updates on the Diagnosis of Osteoporosis Basel Masri

15:20 - 15:45 Musculoskeletal Manifestation of Vitamin D Deficiency,From Evidence to Practice

Atheer Al-Ansari




38


16:15 - 17:40 RA (II) Recommendation and Strategy of Treatment in Rheumatology Arthritis Co-Sponsored by RA SIGChairpersons: Lai-Shan Tam, Adel AlAwadhi

16:15 - 16:50 New Pathways and Informatics Approaches to Target Discovery and Application

Iain McInnes

16:50 - 17:15 Advances in Rheumatoid Arthritis Paul Emery

17:15 - 17:40 Early Diagnosis and Strategies of Deep Remission in RA Zhanguo Li

17:55 - 18:55 Symposium Sponsored by Chugai Pharma

Chairpersons: Chang Youh Tsai, Dae Hyun Yoo17:55 - 18:55 Experience of Tocilizumab Treatment in Taiwan Kuang-Yung Huang

Efficacy of Tocilizumab in RA Patients Yoshiya TanakaCurrent Evidence of IL-6 Signal Inhibition in RA Tsutomu TakeuchiSumming Up Yamamoto Kazuhiko



39

Sheikh Rashid Hall A07:30 - 08:30 Vasculitis SIG / Business Meeting

08:30 - 09:15 Combined Plenary Session I Sheikh Rashid Hall F08:30 - 09:15 Why Should Rheumatologists Know Genetics? Kazuhiko Yamamoto



11:45 - 13:00 Paediatric Rheumatology IChairpersons: Elsadeg Sherif, Yukinori Okada

11:45 - 12:10 Auto-Inflammatory Disease in Childhood Caifeng Li

12:10 - 12:35 Familial Non-Inflammatory Arthropathy Sulaiman Al-Mayouf

12:35 - 13:00 From Pediatric to Adult: Making Transition Easier Christine Bernal

14:30 - 15:45 Genetic & Molecular (I)Chairpersons: Kusuki Nishioka, Leong Khai Pang

14:30 - 14:55 The INTERSPA Study: Diagnostic Properties of Anti-CD74 Antibodies in Early Axial Spondyloarthritis

Nelly Ziade

14:55 - 15:20 The Mysterious Triangle: HLA B27, Sacroiliac Joints and Spondyloarthritis.

Prakash Pispati

15:20 - 15:45 Thymus Gland Immunology in Rheumatic Diseases. Molecular, Cellular and Clinical Levels.

Mark Goloviznin


16:15 - 17:40 Genetics in Rheumatology (II), Co-Sponsored by Genetics SIGChairpersons: Ved Chaturvedi, James Cheng-Chung Wei

16:15 - 16:50 Genetic Risk Factors in Rheumatic Disease Yukinori Okada

16:50 - 17:15 Linking APLAR Genetic Researchers Thru Ethical Bio-Banking Michael Tee

17:15 - 17:40 Personalized Rheumatology - The Role of the Genes Leong Khai Pang




40

Sheikh Rashid Hall B08:30 - 09:15 Combined Plenary Session I Sheikh Rashid Hall F08:30 - 09:15 Why Should Rheumatologists Know Genetics? Kazuhiko Yamamoto



11:45 - 13:00 Oral Abstract Presentations PresentersChairpersons: Song Yeung, Humeira Badsha

11:45 - 11:55A Rituximab dosing protocol based on peripheral B cell depletion achieves good disease control at significantly lower dose in Rheumatoid arthritisG. ANTONY, M. JOSEPH, S. SREENATH, P. RAGHAVAN, P. SHENOY

Glindow Antony

11:55 - 12:05

Quantitative radiographic analysis of interstitial lung disease associated with rheumatoid arthritisJ. S. LEE, H. J. KIM, Y.-J. HA, E. H. KANG, Y. J. L LEE, Y.-B. PARK, J.-Y.CHOE, Y. W. SONG, E. Y. LEE

Jeong Seok Lee

12:05 - 12:15

Secukinumab Provides Early and Long Lasting Pain Relief in Biologic-naïve Patients with Psoriatic Arthritis: 2-year Results from the FUTURE-2 StudyI. B. MCINNES, P. J. MEASE, G. SCHETT, B. KIRKHAM, V. STRAND, N. WILLIAMS, T. FOX, L. PRICOP, S. JUGL, K. K. GANDHI

Iain B McInnes

12:15 - 12:25A qualitative study on influencing factors of medication compliance in patients with systemic lupus erythematosusS. CHEN,#, L. LI, Q. ZHAO, Y. CUI, Z. GU, L. LI

Zhifeng Gu

12:25 - 12:35The impact of Rheumatoid Arthritis on female sexual function: a systematic review and meta analysisC. ZHOU, Q. ZHANG, X. XU, Z. GU

Congcong Zhou

12:35 - 12:45Can achieving remission improve work ability and quality of life in early Rheumatoid Arthritis (RA) patients? A prospective cohort studyS. H. M. LAM, I. T. H. CHENG, L. S. TAM

Ho Man Lam

12:45 - 12:554 - The impact of Systemic sclerosis on health-related quality of life assessed by SF-36: A systematic review and meta-analysis

Lin Li

APLAR BEST ABSTRACTS AWARDS14:30 - 15:45 Oral Abstract Presentations Presenters

Chairpersons: Zhanguo Li, Syed Atiqul Haq

14:30 - 14:40

Evaluating Placental Transfer of Certolizumab Pegol and Polyethylene Glycol During Pregnancy: Results from CRIB, a Prospective, Postmarketing, Multicenter, Pharmacokinetic StudyJ. BARDOS, B. KHAN, X. MARIETTE, B. ABRAHAM, A. FLYNN, F. F €ORGER, A. MOLTO,R.-M. FLIPO, A. VAN TUBERGEN, L. SHAUGHNESSY, J. SIMPSON, M. TEIL, E. HELMER, M. WANG, E. CHAKRAVARTY

Bhavna Khan



41

14:40 - 14:50

Interim results from PROOF – a 5-year observational study of long-term disease outcome in axial spondyloarthritis — subanalysis from KuwaitA. AHMED ALENIZI, T. FADEL, H. DALLE

Ahmed Alenizi

14:50 - 15:00 A novel COL5A1 mutation in the classic type of Ehlers-Danlos syndrome in a Chinese family

Yue Yang

15:00 - 15:10

Macrophage activation syndrome (MAS) in systemic lupus erythematosus (SLE): a multicenter, case-control study in ChinaY. YANG, A.-C. LIU, Y. JIA, M.-T. LI, S. CHEN, S. YE, X.-Z. ZENG,Z. WANG, J.-X. ZHAO, X.-Y. LIU, J. ZHU, Y. ZHAO, X.-F. ZENG, Z.-G. LI

Yue Yang

15:10 - 15:20Achieving early disease control and reducing indirect cost – The CRYSTAL registry in Hong Kong rheumatoid arthritis patients T. H. CHENG, M. C. WAN, L. S. TAM

Isaac Cheng

15:20 - 15:30

Imbalance of Th1, Th2, Th17, and Treg related to Proteinuria, Anti Nuclear Antibody Level, and Arthritis in Pristane Induced Lupus MiceH. KALIM, M. Z. PRATAMA, M. V. MAHARDIKA, S. N. FITRIA,F. ALBINSAID, T. KHALASHA, A. P. WULANDARI, T. W. IMAN,K. HANDONO

Muhammad Vardian Mahardika

15:30 - 15:40

Serum soluble interleukin-2 receptor levels reflect disease activity in IgG4-related disease and primary Sjögren’s syndromeM. AKIYAMA, T. SASAKI, Y. KANEKO, H. YASUOKA, K. SUZUKI, K.YAMAOKA,T. TAKEUCHI

Mitsuhiro Akiyama

15:40 - 15:50

Oxidized albumin as a predictive tool for cardiovascular events among rheumatoid arthritis patients treated with biological agents: a case-control study. K. KIZAKI, F. YAMASHITA, N. FUNAKOSHI, M. ITOI

Kazuha Kizaki

APLAR BEST ABSTRACTS AWARDS15:55 - 16:15 COFFEE BREAK & POSTER VIEWING

16:15 - 17:55 TherapeuticsChairpersons: Fouad Fayad, Asad Zoma

16:15 - 16:40 Diet in Rheumatoid Arthritis Humeira Badsha

16:40 - 17:05 The Wide Use of Rituximab in Rheumatology Pactice:Results of Systematic Literature Reviews

Hani AlMoallim

17:05 - 17:30 Challenges With Biologic Therapies Mustafa Al Izzi

17:30 - 17:55 Long Term Adherence of Etanercept in Iraqi Patients with Rheumatoid Arthritis: A Five-Year Data from Local Registry

Nizar Abdulateef

17:55 - 18:55 The Chronic Disease ManagementPatient Compliance, Patient Adherence, Patient Concordance

Mohammad Farghaly

20.30 - DINNER by Invitation Only



42

Sheikh Rashid Hall F08:30 - 09:15 Combined Plenary Session I

08:30 - 09:15 Prevention and Treatment of Early Rheumatoid Arthritis Johannes W.J. Bijlsma

09:15 - 10:00 Combined Plenary Session II

09:15 - 10:00 Approach to a Difficult RA Patients John Cush10:00 - 10:30 COFFEE BREAK & POSTER VIEWING

10:30 - 11:45 ACR SymposiumChairpersons: Kazuhiko Yamamoto, Munther Khamashta

10:30 - 10:35 Introduction Carol Langford

10:35 - 11:10 New Therapies for SLE Michelle Petri

11:10 - 11:45 Treatment of ANCA-Associated Vasculitis Carol Langford


13:30 - 14:45 Vasculitis (II)- To Familiarize with Highlight Advancements of Vasculitis Research in Asia Pacific Region, Co-Sponsored by Vasculitis SIGChairpersons: Fereydoun Davatchi, Hani AlMoallim

13:30 - 13:55 ANCA Associated Vasculitides- Japanese Experience in Comparison With Other Ethnicities

Yoshihiro Arimura

13:55 - 14:20 The Clinical Characteristics of Chinese Vasculitis Patients Xinping Tian

14:20 - 14:45 Vascular Involvement in Behcet’s Syndrome Juma AlKaabi

14:45 - 15:15 CLOSING CEREMONY & APLAR BEST ABSTRACT AWARDS



43

Sheikh Rashid Hall C & D08:30 - 09:15 Combined Plenary Session I Sheikh Rashid Hall F08:30 - 09:15 Prevention and Treatment of Early Rheumatoid Arthritis Johannes W.J. Bijlsma

09:15 - 10:00 Combined Plenary Session II Sheikh Rashid Hall F09:15 - 10:00 Approach to a Difficult RA Patients John Cush10:00 - 10:30 COFFEE BREAK & POSTER VIEWING

10:30 - 11:45 SpondyloarthritisChairpersons: Nelly Ziade, Bassel El-Zorkany

10:30 - 10:55 Long Term Remission in Axial Spa Ved Chaturvedi

10:55 - 11:20 Beyond The Usual in Ankylosing Spondylitis Haider Al Attia

11:20 - 11:45 Why is Arabia in Need for a Rheumatology Nurse Khalid AlnaqbiNafaja Salem


13:30 - 14:45 The Great Debate

13:30 - 14:45 The Great APLAR Debate Waleed AlShehhi John Cush



44

Sheikh Rashid Hall A08:30 - 09:15 Combined Plenary Session I Sheikh Rashid Hall F08:30 - 09:15 Prevention and Treatment of Early Rheumatoid Arthritis Johannes W.J. Bijlsma


10:30 - 11:45 Non-Clinical Aspects in RheumatologyChairpersons: Sami Salman, Ian Reid

10:30 - 10:55 Patterns of IgG Glycosylation Distinguishes Different Clinical Phenotypes of Antiphospholipid Antibody Positivity

John Axford

10:55 - 11:20 Effects of Some Non Steroidal Anti-inflammatory Drugs (NSAIDs) on Ovulation in Women

Sami Salman

11:20 - 11:45 Postgraduate Medical Training in the UK for International Medical Graduates

Asad Zoma


13:30 - 14:45 Pediatric Rheumatology IIChairpersons: TBA , Sulaiman Al-Mayouf

13:30 - 13:55 Ultrasound in Pediatric Rheumatology Clinics: The Clinician’s Tool Alice Leahy13:55 - 14:20 Auto-Inflamatory Disorders in Children Basil Fathalla

14:20 - 14:45 Adult vs Childhood onset - Systemic Lupus Erythematosus Reem Abdwani



Sheikh Rashid Hall B08:30 - 09:15 Combined Plenary Session I Sheikh Rashid Hall F08:30 - 09:15 Prevention and Treatment of Early Rheumatoid Arthritis Johannes W.J. Bijlsma


10:30 - 11:45 Oral Abstract Presentations PresentersChairpersons: Bhavna Khan, Xinping Tian

10:30 - 10:40Economic Benefits of Rheumatology Clinical Trials - Cannock Experience.P. JOSHI, J. EDWARDS, V. CHALAM, T. SHEERAN

Piyush Joshi

10:40 - 10:50

Prevalence and risk factors of musculoskeletal complaints in a multi-ethnic Surinamese population: preliminary results of the COPCORD Suriname studyN.HO-A-THAM, R.BASANTRAM, R. WITTOEK, Y. VANLANDEWIJCK,W. DANKAERTSA

Nancy Ho-A-Tham

10:50 - 11:00The biologic therapy survival in patients with rheumatoid arthritis. Data from Moscow Arthritis Registry (MERA).E. KOLTSOVA, G. LUKINA, E. SHMIDT, E. ZHILYAEV

Ekaterina Koltsova

11:00 - 11:10Peripheral manifestations occur predominantly in patients with late-onset spondyloarthritis patientsY. ENDO, K. FUJIKAWA, A. MIZOKAMI, M. MINE, T. KOGA, A.KAWAKAMI

Yushiro Endo

11:10 - 11:20

Correlations between clinical and ultrasound scores of peripheral enthesitis and disease activity scores in a cohort of Spondyloarthritis (SpA).A. HADDOUCHE, S. SLIMANI, S. HAID, S. BENCHEIKH, A.ABDESSEMED, N. BRAHIMI, A. LADJOUZE

Samy Slimani

11:20 - 11:30Design and Early Clinical Development of SEL-212, a Non-Immunogenic Pegylated Uricase for the Treatment of Chronic Severe GoutE. SANDS, A. J. KIVITZ, W. DEHAAN, L. JOHNSTON, T. K.KISHIMOTO

Takashi Kishimoto

11:30 - 11:40

Elevation of serum PCSK9 concentrations and its correlation with C-reactive protein, but not atherogenic lipids in patients with systemic lupus erythematosusC. FANG, T. LUO, X. CHEN, L. LIN

Chenglong Fang

APLAR BEST ABSTRACTS AWARDS12:10 - 13:30 PRAYER FOLLOWED BY LUNCH



46


Sheikh Rashid Hall B13:30 - 14:45 Oral Abstract Presentations Presenters

Chairpersons: Abdulatif Alarfaj, Ved Chaturvedi

13:30 - 13:40

Carotid Plaque Formation is associated with Bone Mineral Density as well as Inflammatory Burden in Rheumatoid Arthritis: A 5-Year Prospective StudyJ. W. KANG, N. R. KIM, J. S. EUN, J. H. KIM, J. Y. KANG, G. B. BAE, S. J.LEE, E. J. NAM, Y. M. KANG

Jong Wan Kang

13:40 - 13:50Human Papillomavirus infection is associated with risk of Sjogren’s Syndrome: A nationwide population-based cohort studyJ. C. WEI, J.-Y. HUANG, H.-H. CHEN

James Cheng-Chung Wei

13:50 - 14:00Treatment Resistant Adult onset Polymyositis responded to Rituximab-Case presentation A. M. ARIF MAROOF

Avin Maroof

14:00 - 14:10

Elevated salivary syndecan-1 levels reflect salivary gland dysfunction and immune dysregulation in patients with Sjögren’s syndromeE. J. NAM, J. W. KANG, J. S. EUN, N. R. KIM, S. J. LEE, K. H. SA, G. B. BAE,Y. M. KANG

Na Ri Kim

14:10 - 14:20

Can achieving sustained DAS remission prevent arterial stiffness progression in early rheumatoid arthritis - a post-hoc analysis of a randomized controlled studyL. P. TAM, Q. SHANG, E. K. LI, P. C. WONG, K. Y. KWOK, E. W.KUN, I. C. YIM,V. K. LEE, R. M. YIP, S. H. PANG, V. W. LAO, Q.MAK, I. CHENG, X. LAU, T. K. LI,T. Y. ZHU, A. P. LEE, L.-S. TAM

Isaac Cheng

14:20 - 14:30

Efficacy and safety of baricitinib versus placebo or adalimumab in patients with moderately-to-severely active rheumatoid arthritis and inadequate response to methotrexate: summary results from the 52-week phase 3 RA-BEAM studyPeter C Taylor, Marek Krogulec, Anna Dudek, Jean Dudler, Edit Drescher, Regina Cseuz, Rasa Kausiene, Daina Andersone, Dalia Unikiene, Juan Sanchez Burson, Ricardo Blanco Alonso, Zdeněk Dvořák, Andrei Ghizdavescu, Ildiko Irto, Esbjörn Larsson, Natalia Bello, Jane Barry, Frederick Durand, Thorsten Holzkämper, Susan Otawa, Stephanie de Bono, Edward C Keystone, Andrea Rubbert-Roth, Bernard Combe, Inmaculada De La Torre and the RA-BEAM Investigators

Prof. Paul Emery

14:30 - 14:40Impact of training on Primary Care Physicians by rheumatologists for early diagnosis of inflammatory arthritis

Rami Fawzi Magliah

APLAR BEST ABSTRACTS AWARDS


47

POSTER PRESENTATIONS


ABS013 Painful hands in patients with type 2 diabetes mellitus, what ultrasound could tell us?A. F. ABOGAMAL, E. MAHMOUD, Y. NASSAR, A. HAMED, A. E.AMER, S ABDULHAKIM, S. ABDELLATIF, A. F. ABDELAZIZ

ABS019 Changes in IgG RF and ACCP in response to traditional treatment of RA.H. M. AL ATTIA

ABS015 Prevalence of Baker's cyst among female patients with knee osteoarthritis, an ultrasonographic study, in Egypt.A. F. ABOGAMAL, S. ABDULHAKIEM, Y. A. YASEIN, H. SAAD, M. A. H. SHOUKEER

ABS016 Safety and efficacy of Leflunomide - Methotrexate combination in RA therapy,follow-up ultrasonographic studyA. F. ABOGAMAL, H. ALY, S. GHANEM, H. SAAD

ABS018 Serological changes in the course of treatment with Tocilizumab (TCZ) therapy alone for rheumatoid arthritis.H. M. A. ATTIA

ABS012 Prevalence of low vitamin D and disability among Egyptian female patients with rheumatoid arthritisA. F. ABOGAMAL, Y. A. YASEIN, A. E. MANSOUR, Y. NASSAR, E.MAHMOUD,A. F. ABDALAZIZ, M. M. SHABAN

ABS014 Prevalence of Lower Limb Traction Apophysitis among Children with Low Vitamin D and Secondary Hyperparathyroidism - Ultra Sonographic StudyA. F. ABOGAMAL, E. MAHMOUD, A. A. ABDELAZIZ, S. ABDELATIF, M. A. HASUNAHEMEDA, A. FATHYABDALAZIZ, M. A. H. SHOUKEER

ABS021 Anti thyroid peroxidase antibodies (TPO abs) in rheumatoid arthritis: UAE perspectivesH. M. A. ATTIA

ABS026 Hyperuricaemia in Hong Kong Chinese Patients with Psoriatic Arthritis (PsA)T. L. LAI, C. W. YIM

ABS038 Utility of serum ferritin as a marker of disease activity in childhood systemic lupus erythematosusN. ALMUTAIRI, A. ALJASER, A. ALMUTAIRI, M. ALSHAIKH, S. M. ALMAYOUF

ABS042 Comparison of efficacy and safety of mycophenolatemofetil and intravenous pulse cyclophosphamide as induction therapy in proliferative lupus nephritisA.-A. EBRAHIMI, A. M. MAHDAVI, F. EBRAHIMI, A. KHABBAZI

48


ABS046 Recent changes of radiological findings and patients’ background of rheumatoid hip and knee TBA

ABS033 Long-term outcome of treatment with disease-modifying antirheumatic drugs in patients with palindromic rheumatismA. KHABBAZI, M. GOLI

ABS034 Validation of the international criteria for Behcet’s disease in Azeri PopulationA. KHABBAZI, L. DELNABI, A. EBRAHIMI

ABS037 Assessing outcome of adults with juvenile idiopathic arthritis in a tertiary centerH. ALDALAAN, R. ALFADA, B. ALHAYMOUNI, A. A. SHAIKH, M.MOHAMMED,A. EDALI, S. M. AL-MAYOUF

ABS040 Frequencies of HLA-B5/51 and B27 in patients with idiopathic uveitis and Behçet’s dis-ease comparing control groupS. SHENAVANDEH, K JAHANSHAHI, E AFLAKI

ABS048 Rapid change of the capillary morphology and architecture in dermatomyositis patient with treatment responseJ. JUNG, S.-J. PARK, I.-H. CHOI, Y.-S. KIM, H.-S. KIM

ABS049 Rapid progression of the skin sclerosis precipitated by a pheochromocytoma in a patient with systemic sclerosisJ. JEONG, H. KIM, H.-S. KIM

ABS057 A status report of medical treatment for rheumatic patients’ osteoporosisN. NAKAGAWA, T. HARADA, H. TAKAYAMA, K. AOKI, K. KISHIMOTO

ABS058 Drug survival rate of disease modifying anti-rheumatic drugs in Thai rheumatoid arthritis patientsP. AKARAWATCHARANGURA, C. WATTANAKUL, M. OSIRI

ABS039 Phenotypic characteristics and outcome of juvenile dermatomyositis in Arab childrenS. M. AL-MAYOUF, N. ALMUTIARI, M. MUZAFFER, R. SHEHATA, A.AL-WAHADNEH,R. ABDWANI, S. AL-ABRAWI, M. ABU-SHUKAIR, Z.EL-HABAHBEH4, A. ALSONBUL

ABS054 Immune Modulation Effects of Curcumin in Pristane-Induced Lupus MiceTBA


49



ABS079 Concurrent infection with tuberculosis and cryptococcus in a patient with rheumatoid arthritis C.-N. SON, S.-Y. LEE, H.-J. JEONG, J.-M. KIM, S.-H. KIM

ABS086 The Efficacy and Safety of Febuxostat: A Hospital Case SeriesC. R. NG, Y. L. LOH

ABS063 Additional therapy with a bDMARD or a Jak-inhibitor is superior to combination therapy with multiple csDMARDs in RATBA

ABS064 Improvement in disease activity and functional disability following treatment with biosimilar adalimumab in patients with ankylosing spondylitisV. K. RAO, A. SUDHAKAR

ABS068 The association between 10-year fracture risk by FRAXÂ® and osteoporotic fractures with disease activity in patients with rheumatoid arthritis abstractR. PHUAN-UDOM, N. LEKTRAKUL, A. KOOLVISOOT, E. AROMDEE,P. CHIOWCHANWESAWAKIT, C. MUENGCHAN, W. KATCHAMART

ABS075 Progressive reduction of the serum complement levels is a risk factor for relapse in patients with systemic lupus erythematosusY. MIYAWAKI, K.-E. SADA, Y. ASANO, Y. YAMAMURA, K. HAYASHI, S.HIRAMATSU,K. OHASHI, M. MORISHITA, E. KATSUYAMA, H.WATANABE, M. TAKANO-NARAZAKI, N. TOYOTA-TATEBE, Y.MATSUMOTO, T. KAWABATA, J. WADA

ABS080 Effect of stretching and strengthening exercise in the management of Lateral EpicondylitisK. M. NURUZZAMAN, A. S. MOZAFFAR, K. M. RAHMAN, A. K. M.SALEK, A. EMRAN

ABS081 The serum cytokines predict disease activity in systemic lupus erythematosus N. RUCHAKORN, P. NGAMJANYAPORN, T. SUANGTAMAI, P.PISITKUN

ABS083 Improvement of Biologic Safety - A Biologic Injection Audit C. Y. SHUEN, L. P. FAN

ABS090 Clinical Outcomes Of Knee Osteoarthritis Patients Included In The Osteoarthritis Multidisciplinary Clinic (Oamdc) Of The Philippine General Hospital From 2015-2016TBA

ABS070 A consistency analysis of recommendations from global CPGs of goutY. YU, D. WANG, Q. ZHOU, C. WANG, X. MA, Y. GAO, X. SONG,H. WANG, S. XIAO,Q. WANG, Y. CHEN, X. ZENG,

50



ABS072 Ultrasonography of major salivary glands in Sjögren’s syndrome W. KRAIKRIANGSRI, P. NGAMJANYAPORN, S. JAOVISIDHA

ABS082 Decoy Receptor 3 down-regulates Centrosomal Protein 70kDa in Specifically Rheumatoid Synovial FibroblastsK. FUKUDA, Y. MIURA, T. MAEDA, S. HAYASHI, R. KURODA

ABS084 Impact of Premorbid Infection on Onset and Disease Activity of Rheumatoid ArthritisR. ZHANG, M. SHAO, J.HE, J. CHEN, X. CHEN, J. LI, X. LI, C. LI,Y. JIA, L. REN, L. WU, Z. LI

ABS107 Increased semaphorin3A/semaphorin4D ratio and its role in patients with ankylosing spondylitisY.-J. HA, EH KANG, YW SONG, YJ LEE

ABS111 Methyl Gallate Inhibits Osteoclast Formation And Function Through Suppressing The Akt And Btk-Plc2-Ca2+ Signaling, And Prevents Lps-Induced Bone LossC. H. CHUNG, C.-H. LEE, J. M. BAEK, J.-Y. KIM, M.- S. LEE

ABS092 Type 1 interferon regulates the disease activity of rheumatoid arthritis by inducing interleukin-6M. NAKAYAMA, Y. SAKUMA, K. YANO, Y. NIKI, K. IKARI

ABS094 The efficacy of biologics to pinch powers and grip powers in patients with rheumatoid arthritisT. ORIGUCHI, K. YOSHIDA, T. SUZUKI, A. OKADA, A. TAKATANI,T. SHIMIZU,M. UMEDA, A. NISHINO, T. KOGA, S.-Y. KAWASHIRI,N. IWAMOTO, K. ICHINOSE,H. NAKAMURA, A. KAWAKAMI

ABS096 Towards determining early referral criteria for patients with suspected inflammatory arthritis presenting to primary care physicians: A cross sectional studyH. ALMOALLIM, N. JANOUDI, S. ATTAR, M. GAROUT, S.ALGOHARY, M. I. SIDDIQUI,H. ALOSAIMI, A. IBRAHIM, A.BADOKHON, Z. ALGASEMI

ABS099 Long-term prognosis and predicting factors of Chinese patients with antiphospholipid syndromeTBA

ABS101 Inflammation Is Associated with Intra-Articular and Peri-Articular Bone Loss in Psoriatic Arthritis Compared to Healthy Controls: an HR-pQCT StudyDWU, JF GRIFFITH, Y JIANG, P WONG, Edmund K. LI, M LI, TenaK. LI, Tracy Y. ZHU, Vivian W. HUNG, LQIN, L.-S. TAM

ABS102 Long-term prognosis and predicting factors of Chinese patients with antiphospholipid syndromeTBA

51



ABS103 Clinical Characteristics and Risk Factors for Thrombotic Microangiopathy in Primary Antiphospholipid SyndromeZ JIULIANG, S YIDUO, z PU, W QIAN, L MENGTAO, Z XIAOFENG

ABS104 Clinical features and progress of pulmonary artery hypertension according to underlying rheumatic diseases: results from a Korean nationwide registryMR SEO, HJ RYU, H.-J. CHOI, HJ BAEK

ABS105 Risk of methylprednisolone pulse therapy and efficacy of adjunctive steroid therapy for connective tissue disease patients with pneumocystis pneumoniaY ABE, T ANDO, Y ENDO, K TADA, K YAMAJI, N TAMURA

ABS106 Baseline peripheral blood neutrophil-to-lymphocyte ratio could predict survival in patients with adult polymyositis and dermatomyositis: A retrospective study.Y.-J. HA, J HUR, DJ GO, EH KANG, JK PARK, EY LEE, EB LEE, YWSONG, YJ LEE

ABS108 Severe And Rapid Worsening Interstitial Lung Disease In Ra Patients With Introduction Of A Tnf Inhibitor - Two Case Reports C. N. RAJAPAKSE

ABS113 Cocaine-induced Midline Destructive Lesions Mimicking ANCA associated vasculitisM ZABIHIYEGANEH, A MIRZAEI

ABS116 Positive conversion of MPO-ANCA is a promising biomarker for relapse in ANCA-associated vasculitis; subgroup analysis of nationwide prospective cohort studiesH. WATANABE , K.-E. SADA , M. HARIGAI , H. MAKINO, AND FOR RESEARCH COMMITTEE OF INTRACTABLE VASCULITIS SYNDROME AND RESEARCH COMMITTEE OF INTRACTABLE RENAL DISEASE OF THE MINISTRY OF HEALTH, LABOUR, AND WELFARE OF JAPAN

ABS119 The burden of psoriatic arthritis in AsiaW. C. TSAI, J. T. LI-YU, H. E. JONES, P. V. S. ESTRELLA, L. J.LLAMADO

ABS120 Erosion depth predicts erosion progression in patients with early RA: a longitudinal analysis using HR-pQCTJ. YUE, J. F. GRIFFITH, J. XU, F. XIAO, L. SHI, D. WANG, P. WONG, E. K.LI, M. LI, T. K. LI,T. Y. ZHU, L. QIN, L.-S. TAM

ABS095 Adalimumab Impact on Fatigue measured by FACIT-F: A Study of Rheumatoid Arthritis Patients in Saudi Arabia N. JANOUDI, N. OMRAN, W. HUSEEIN, H. ALOSAIMI, M. BAAMER,M. IRFANULLAHSIDDIQUI, O. FATHADDIEN, H. ALMOALLIM

52


ABS098 Can achieving sustained Minimal Disease Activity (MDA) prevent progression of subclinical atherosclerosis? A two-year prospective cohort study in Psoriatic Arthritis I. T. CHENG, Q. SHANG, E. K. LI, P. C. WONG, L. H. TAM, T. Y.ZHU, M. M. CHANG,J. J. LEE, C.-K. WONG4, A. P. LEE, L.-S. TAM

ABS100 Short-term efficacy and safety of new biological agents targeting the IL-6, IL-12/23 and IL-17 pathways for active psoriatic arthritis D. WU, J. YUE, L.-S. TAM

ABS109 Study Of The Role Of Calcium Homeostasis, And Vitamin D Deficiency In Premenopausal Sle Egyptian Patients And Its Relation To Disease ActivityTBA

ABS131 The Relatioships Among Leptin, Resistin, Visfatin, Transforming Growth Factor (TGF)- B Level and severity of Knee Osteoarthritis Patients with Obesity R. U. PARTAN, R. HIDAYAT2, M. MUKTI

ABS126 Inhibition of Spleen Tyrosine Kinase Improves Renal Pathology and Reduces Lymphocyte Activation in Two Murine Models of Systemic Lupus Erythematosus J. A. DI PAOLO, C. POHLMEYER, Z.-H. CUI, G. MIN-OO, I.MIKAELIAN, R. BROCKETT,B. P. MURRAY, R. BANNISTER, J. KIM, FMATZKIES

ABS130 MicroRNA-499 in Behçet Disease: Possible Association with Disease ActivityTBA

ABS122 High incidence of ARONJ (antiresorptive agents related osteonecrosis of the jaw) in patients with autoimmune diseasesM. DOI, Y. FUJIEDA, Y. OGATA, N. OHNISHI, S. ABE, R. HISADA,M. KATO, K. OKU,T. BOHGAKI, O. AMENGUAL, S. YASUDA1, TATSUMI

ABS123 Prevalence of Thyroid diseases in SLE patients among Saudi populationR. ALKHATHAMI, S. ALJOHANI, M. Y. I. ALHOMOOD

ABS124 Comparision of efficacy of Biosimilar Adalimumab therapy in Ankylosing Spondylitis patients - 6 months Vs 1 yearTBA

ABS125 Altered dose regime of Infliximab in Ankylosing Spondylitis – Can Biosimilar be equally effectiveS. BANDYOPADHYAY

ABS136 Translation, Cultural Adaptation and Validation of the English “Short Form SF 12v2” into Bengali in Rheumatoid Arthritis PatientsN. ISLAM, I. H. KHAN, N. FERDOUS, J. J. RASKER


53



ABS140 Patient Reported Outcomes Survey of Employment among patients with Rheumatoid Arthritis in the Gulf-Levant region (PROSE-RA Survey)S. EL EMADI, H. BADSHA, K. ALAWNEH, F. FAYAD, S. HAMMAD, H.SALAHEDIN, M. HOBEIKA, R. BADDOURA

ABS141 Hydroxychloroquine and risk of cancer in patients with primary Sjögren syndrome: propensity score matched landmark analysisY.-F. FANG, Chang-Fu KUO, Yen-Fu CHEN, Ting-Ting CHUNG,Lai-Chu SEE, Kuang-Hui YU, Shue-Fen LUO, Jenn-Haung LAI

ABS143 Impact Of Anxiety And/Or Depression On Pain, Stiffness, And Physical Function In A Sample Of Patients With Primary Osteoarthritis Of The Knee: A Cross Sectional StudyS. SALMAN, A. ABDULAMEER

ABS144 Effects of short term intake of some commonly used NSAIDs on ovulation in young womenS. SALMAN, A. NAJEM, A. ALZUHAIRI

ABS147 Efficacy Of Knee Tape In The Management Of Osteoarthritis Of The Nee:Blinded Randomized Controlled TrialS. SALMAN, R. KADHIM

ABS137 Macroscopic and Microscopic Evaluation of Full Colon in Patients with Ankylosying SpondylitisN. FERDOUS, N. ISLAM S. M. ISHAQUE, S. AKHTER, M. KAMAL,F. B. N. J. J. RASKER

ABS142 Alendronate Sodium In Osteoarthritis: Effects On Anabolic, Cartilage Degredative Markers, Circulating Leptin And The Clinical ActivityS. SALMAN, S. A. A. KADHIM, H. M. JAWAD

ABS135 Melioidosis With Septic Oligoarthritis Without Fever Mimicking Rheumatological DiseaseP. D. RATH, S. BHASIN, S. PANDEY, S. SRIVASTAVA

ABS128 Efficacy of Sarilumab Plus csDMARDs in Subgroups of Patients With Rheumatoid Arthritis and an Inadequate Response to TNF Inhibitors G. R. BURMESTER, H. VAN HOOGSTRATEN, E. K. MANGAN, Y. LIN,N. M. H. GRAHAM, T. KIMURA, P. HRYCAJ

ABS163 The liver X receptor regulates toll-like receptor-driven cytokine release according to genotype of -1830 T > C polymorphism in monocyte derived macrophageW.-Y. BAEK, H.-A. KIM, J.-Y. JUNG, M.-H. HAN, S.-H. LEE, S.-W.LEE, K.-S. RYU, C.-H. SUH

ABS165 Interleukin-4 enhances IgG4 class-switching and contributes to plasmablast and plasma-cell differentiation with interleukin-21 in CD40-dependent manner in IgG4-related Disease M. AKIYAMA, H. YASUOKA, K. YOSHIMOTO, T TAKEUCHI

54



ABS152 Prediction of bone mineral density changes in patients with rheumatoid arthritisT. TOMIZAWA, H. ITO, M. FURU, M. HASHIMOTO, M. TANAKA, T.MIMORI3,S. MATSUDA

ABS155 Minimum ten-year results of inset biconvex patella prostheses in total knee arthroplasty in patients with rheumatoid arthritis.K. KIZAKI, F. YAMASHITA, N. FUNAKOSHI, M. ITOI

ABS156 Rheumatologic signs of Fabry diseaseM. OLGA

ABS162 Characteristics of uveitis in patients with ankylosing spondylitis in Korea: a single-center surveyT.-H. KIM, B. S. KOO, J. H. SHIN, J. U. LIM, I.-H. SUNG

ABS500 Rheumatologic Manifestations in HIV-positive Patients in a Tertiary Government Hospital in the PhilippinesG. M. D. GARCIA, M. A. BERNARDO, A. URBANO, E. O. SALIDO

ABS506 Life events observed among patients with Systemic Lupus Erythematosus in the Philippine General HospitalG. PENSERGA, D. GUEVARA, R. BRUNO

ABS151 Effectiveness of triple therapy consisting of glucocorticoid, intravenous cyclophosphamide, and double-filtration plasmapheresis to treat skin sclerosis in diffuse systemic sclerosis K. SUGA, H. YAMASHITA, A. YASHIMA, Y. TAKAHASHI, H. KANEKO

ABS153 Prevalence of HLA-B27 and the association of HLA-B27 and clinical manifestations among axial spondyloarthritis patients N. LIMSAKUL, P. CHIOWCHANWISAWAKIT

ABS589 Prevalence of tuberculosis and outcome of anti-TB therapy among patients with Rheumatological ConditionY. M. SOE, W. L. Y. THANT, P. P. KYAW, P. P. OO, K. L. L. AUNG, C. SOE

ABS590 Outcomes of pregnancy among patients with Rheumatological ConditionsY. M. SOE, W. L. Y. THANT, P. P. KYAW, K. T. Z. WIN, C. SOE

ABS195 Level of chemokines in stimulated whole blood cultures is useful to predict response to anti-TNF therapies in rheumatoid arthritisH. IKEUCHI, T. A. KADIOMBO, M. NAKAZATOMI, T. SAKAIRI, Y.KANEKO, Y. NOJIMA, K. HIROMURA

55



ABS182 A gene module associated with dysregulated TCR signaling pathways in CD4+ T cell subsets in rheumatoid arthritisS. SUMITOMO, Y. NAGAFUCHI, Y. TSUCHIDA, H. TSUCHIYA, M.OTA, K. ISHIGAKI,S. NAKACHI, R. KATO, K. SAKURAI, N.HANATA, S. TATEISHI,H. KANDA1, A. SUZUKI,Y. KOCHI, K.FUJIO, K. YAMAMOTO

ABS191 Exosomal LYVE-1 protein as a new candidate biomarker for disease activity in rheumatoid arthritis D. SHEEN, J. SONG, M. LIM, J. YOO, S. A. KIM

ABS174 Paediatric lupus is a great mimicker, a case seriesL. NAZIR, T. P. UMER, W. HAROON, M. SAAD SALIM, M. JAWED

ABS176 Cross-cultural validation of the disease specific health related quality of life questionnaire LupusQol in the PhilippinesA. J. MIRANDA, E. G. PENSERGA

ABS178 Change in surgically treated cervical spine disorders of Japanese patients with Rheumatoid Arthritis during recent 15 years.T. TSUTSUI, K. SAKURABA, K. KAI, K. TERADA, N. KOHARA, S. KAMURA,K. FUJIMURA, H. MIYAHARA

ABS181 Dyslipidemia In Patients With Lupus Nephritis And Its Association With ProteinuriaS. SAJJAD, S. FARMAN, M. A. SAEED, N. MIR, AHMAD, B. A. BUTT

ABS183 Influence of Aadalimumab administration on worklabor productivity ofin rheumatoid arthritis patientsT. FUKUI, Y. WAGURI-NAGAYA

ABS188 Economic burden on Rheumatoid arthritis patients in a tertiary care hospital of PakistanTBA

ABS189 Efficacy and safety of biosimilar infliximab (©Inflectra) in patients with ankylosing spondylitis: multicenter and observational one year follow-up studyTBA

ABS192 The Effect of Aquatic Exercise on Disease Activity Score in Women with Rheumatoid ArthritisS. M. SAIDMARDANI, M. AGHDASHI, F. ASGHARI, G. K. ZONOUZ,P. ALIZADE

ABS193 Monosodium urate crystal detection in synovial fluid in gout patient by polarized light microscopyTBA

56



ABS167 The superb microvascular imaging is more sensitive than power Doppler imaging in detection of active synovitis in rheumatoid arthritis patientsJ.-S. SONG, G. Y. LEE, S. KIM, S. T. CHOI

ABS168 Impairment of renal function in patients with hyperuricemia may induce atherosclerosis through increased serum homocysteine levelJ. H. PARK, J.-S. SONG, S. T. CHOI

ABS170 Pattern of bone mineral density among elderly housewives, analysis of limited data from a laboratory. TBA

ABS173 Discordance between Spine, hip and wrist T-score measurement on DXA.LUBNANAZIR, TAHIRAPERVEENUMER, TABERASOOL, W. HAROON

ABS179 Effect Of The Metabolic Syndrome On Organ Damage And Mortality In Chinese Patients With Systemic Lupus Erythematosus: A Longitudinal AnalysisL. S. FONG, S. M. TSE, L. Y. HO, C. C. MOK

ABS184 Predicting clinical disease activity index remission at 24 weeks in patients with early rheumatoid arthritis treated with tocilizumab and methotrexate.TBA

ABS187 Ultrasonographic changes of pes anserine syndrome secondary to knee osteoarthritis after local corticosteroid injectionM. GAMAL, S. ELARABY, E. ABDELAZIEM, M. ABOUELAILA, A. FATHY

ABS202 uPAR regulates macrophages polarizationTBA

ABS196 C3 but C4 contribution to renal involvement and prognosis in ANCA-associated vasculitis; Clinical characteristics of Japanese patients with renal involvementS. FUKUI, N. IWAMOTO, A. TAKATANI, T. IGAWA, T. SHIMIZU,M. UMEDA,A. NISHINO, Y. HORAI, Y. HIRAI, T. KOGA, S.-Y.KAWASHIRI, M. TAMAI, K. ICHINOSE, H. NAKAMURA, T.ORIGUCHI, S. SATO, A. KAWAKAMI

ABS201 Secondary antiphospholipid syndrome occurring after hepatectomy in a patient with autoimmune hepatitis.M. SEKI, I. TSUTSUMI, C. YOSHIDA, T. KOMENO, S. YOSHIDA, Y.KOBAYASHI

ABS203 Psoriasiform skin lesions related to anti-TNF-a therapy in SAPHO syndrome: Possible association with paradoxical increased TNF-a expression in pathological tissueX. WU, C. LI, Y. CAO, Y. ZENG, L. LI

57



ABS207 Risk factors for cytomegalovirus viremia after remission induction therapy for antineutrophil cytoplasmic antibody-associated vasculitisK. HAYASHI, M. MORISHITA, K.-E. SADA, Y. ASANO, Y. YAMAMURA, S.HIRAMATSU,K. OHASHI, Y. MIYAWAKI, E. KATSUYAMA, H.WATANABE, M. TAKANO-NARAZAKI,N. TOYOTA-TATEBE, Y.MATSUMOTO, T. KAWABATA, J. WADA

ABS210 Study Of Metabolic Parameters In GoutB. VAIDYA, B. UPRETI, S. NAKARMI, H. BARAL

ABS213 Drug-free remission in patients with rheumatoid arthritis: data from Korean Intensive Management of Early Rheumatoid Arthritis (KIMERA)S. M. JUNG, J. Y. PYO, E. S. PARK, H.-J. PARK, S.-W. LEE, J. J. SONG,S.-K. LEE, Y.-B. PARK

ABS221 Prevalence Of Metabolic Syndrome Among Filipino Patients With Psoriatic Arthritis: A Single Center ExperienceTBA

ABS197 Efficacy and safety at 52 weeks of daily clinical use of tofacitinib in patients with rheumatoid arthritis in clinical practice.Y. TSUJI, T. ARAMAKI, K. KOJIMA, S. KURUSHIMA, K.TERADA, K. EGUCHI, Y. UEKI, A. KAWAKAMI

ABS199 Efficacy of monotherapy of the biologic DMARDs in patients with rheumatoid arthritis: real life data from the Hong Kong Biologics RegistryR. T. H. WAN, B. L. S. FONG1, C. C. MOK

ABS200 Effects of an exercise therapy on systemic biomarkers for cartilage metabolismM. AZUKIZAWA, H. ITO, Y. HAMAMOTO, Y. MORITA, A. OKAHATA,T. TOMIZAWA,M. FURU, K. NISHITANI, K. MURATA, H.YOSHITOMI, S. MATSUDA, T. YASUDA

ABS208 Ultrasound assessment of the knee in Japanese populationA. OKAHATA, H. ITO, M. FURU, S. KURIYAMA, S. NAKAMURA, M.ISHIKAWA, Y. MORITA, M. AZUKIZAWA, Y. HAMAMOTO, Y.TANAKA, Y. TABARA, F. MATSUDA, S. MATSUDA

ABS209 Knee extensor strength and disease activity affect walking ability in rheumatoid arthritis patientsY. MORITA, H. ITO, M. FURU, M. HASHIMOTO, M. TANAKA, M.AZUKIZAWA,T. MIMORI, S. MATSUDA

ABS211 Cost effectiveness and efficacy of disease-activity based tapering dose of adalimumab in Spondarthritis patients in Nepal.B. VAIDYA, B. UPRETI, M. GIRI, H. BARAL

58



ABS214 Drug survival of biologic therapies in elderly patients with rheumatoid arthritis: results from the Korean College of Rheumatology Biologics registry S. M. JUNG, E. S. PARK, H.-J. PARK, S.-W. LEE, J. J. SONG, Y.-B.PARK

ABS218 The outcome of posterior stabilized total knee arthroplasty with midvastus approach and non-lateral release for valgus deformity with rheumatoid arthritisK. HOSAKA, S. SAITO, T. OYAMA, H. FUJIMAKI, T. OYAMA, K. ISHIGAKI,R. INAGAKI, Y. TOKUHASHI

ABS223 Juvenile Idiopathic Arthritis Associated With Uveitis In A Single Center ExperienceK. N. KIM

ABS254 The IL-1 and the role in autoimmune diseasesN. MA, Q. GAO, Z. YE, Z. JIANG

ABS238 To correlate the pattern of ANA seen by IFA with ENA (Extractable nuclear antigens) antibodies profile done by line immune assay in lupus patients-Indian data.M. BINDROO, D. R. G. EKBOTE, N. NEGALUR, N. MENDIRATTA, R.GUPTA

ABS239 DAH in ANCA associated vascuilitis- Characteristics & OutcomeD. RAVAL, M. BINDROO, G. EKBOTE, N. NEGALUR, D. TANNA, W.KAZI, V. SINGAL,N. MENDIRATTA, S. BAJAD, R. GUPTA

ABS595 Diet of Indian (Asian) Patients Suffering from RA: Neglect and Ignorance in an Era of Biologic DrugsTBA

ABS236 Constraining Factors that Impact Patient-Perceived Remission Among Patients with Rheumatoid ArthritisR. OCTAVA, M. TEE, N. SIMBULAN, P. REMALANTE

ABS237 Clinical profile of Filipino patients with SLEM. L. TEE, C. A. TEE, K. D. TEE, E. R. JACINTO, A. LANZON

ABS240 Prevalence of isolated PAH in Indian LUPUS patients and its association with autoantibodiesD. RAVAL, M. B. G. EKBOTE, N. NEGALUR, V, SINGAL, R. GUPTA

ABS241 Cluster analysis using antibody profiles of line immunoassay in patients with polymyositis/dermatomyositisK. OHASHI, K.-E. SADA, Y. NAKAI, S. MATSUSHIMA, Y. ASANO, K.HAYASHI,Y. YAMAMURA, S. HIRAMATSU, Y. MIYAWAKI, M.MORISHITA, T. KATSUYAMA,E. KATSUYAMA, H. WATANABE, N.TATEBE, M. NARAZAKI, Y. MATSUMOTO,K. S. WATANABE, T.KAWABATA, J. WADA

59



ABS242 Cost Per Responder Analysis comparing Secukinumab Vs Infliximab For the Treatment of psoriatic arthritis at 48 Weeks in Saudi ArabiaA. ALHAMMAD, A. ALALWAN, N. ALSHEHRI, N. ZAKARIA, L. A.KATEB, A. ZAZAA, P. GUNDA

ABS243 Cost Per Responder Analysis comparing Secukinumab Vs Etanercept For the Treatment of psoriatic arthritis at 24 weeks in Saudi ArabiaA. ALHAMMAD, A. ALALWAN, N. ALSHEHRI, N. ZAKARIA, L. A.KATEB, A. ZAZAA, P. GUNDA

ABS244 Cost Per Responder Analysis comparing Secukinumab Vs Adalimumab For the Treatment of Ankylosing Spondylitis at 52 Weeks in Saudi ArabiaA. ALHAMMAD, A. ALALWAN, N. ALSHEHRI, N. ZAKARIA, L.ALKATEB, A. ZAZAA, P. GUNDA

ABS245 Cost Per Responder Analysis comparing Secukinumab Vs Adalimumab For the Treatment of Psoriatic Arthritis at 48 Weeks in Saudi ArabiaA. ALHAMMAD, A. ALALWAN, N. ALSHEHRI, N. ZAKARIA, L.ALKATEB, A. ZAZAA, P. GUNDA

ABS250 Clinical profile of Filipino pediatric patients with SLEC. A. TEE, M. L. TEE, A. M. SANTIAGO, C. G. ARROYO

ABS253 Outcomes of cementless total hip arthroplasty in rheumatoid arthritisT. IMAGAMA, A. TOKUSHIGE, K. SEKI, T. SEKI, H. OGASA, T.TAGUCHI

ABS255 Bone Mineral Density (BMD) in Indian females with Rheumatoid Arthritis and its Association with Disease Duration.TBA

ABS275 Thymus gland immunology in Rheumatic diseases. Molecular, cellular and clinical levelsM. GOLOVIZNIN, N. LAKHONINA

ABS282 Clinical Spectrum of patients diagnosed with Ankylosing Spondylitis using the Modified New York Criteria seen in Philippine General HospitalTBA

ABS283 Predictors of Outcome of Infections in Filipino Patients with Systemic Lupus Erythematosus in the Philippine General HospitalTBA

ABS284 The effect of biologic agents on nutritional status in patients with rheumatoid arthritis evaluated by serum proteinsY. MIZUNO

60



ABS258 Andersson Lesion as the Presenting Feature of Spondyloarthritis (SPA )M. MUSGRAVE, C. FARAH

ABS257 Achy Joints, Hearing loss and Ulcerative Colitis: Thinking Outside The BoxM. MUSGRAVE, M. ALHAKAM, S. S. MAMMEN, N. HASSAN

ABS259 Etanercept Usage In A Case Of Colchicine- Resistant Familial Mediterranean Fever (Fmf)N. HASSAN , M. MUSGRAVE

ABS261 Effect of Smoking on Disease Activity, Functional Impairment, and Spinal Mobility in a Sample of Iraqi Patients with Ankylosing SpondylitisN. A. JASSIM, N. A. HASHIM

ABS262 Prevalence of Fibromyalgia in Physicians in Training. A Cross Sectional Study TBA

ABS267 Prevalence of Thyroid diseases in SLE patients among Saudi populationR. ALKHATHAMI, I. ALHOMOOD, S. ALJOHANI, M. YOUSEF

ABS271 Ankylosing Spondylitis (As) Patients Failing Biologic Treatment Are Less Able To Work: Survey Results Including Apac And Middle EastA. DEODHAR, V. STRAND, P. G. CONAGHAN, E. SULLIVAN, S.BLACKBURN, H. TIAN, K. GANDHI, S. M. JUGL, R. ALTEN

ABS272 Psoriatic Arthritis (Psa) Patients Failing Biologic Treatment Have Poor Outcomes: Survey Results Including Apac And Middle East R. ALTEN, V. STRAND, A. DEODHAR, E. SULLIVAN, S. BLACKBURN,H. TIAN, K. GANDHI, S. M. JUGL, P. G. CONAGHANP. G. CONAGHAN, V. STRAND, A. DEODHAR, E. SULLIVAN, S.BLACKBURN, H. TIAN,K. GANDHI, S. M. JUGL, R. ALTEN

ABS273 Appropriate Psoriatic Arthritis (Psa) Treatment Is Delayed For Years: Multi-National Survey Results Including Asia Pacific (Apac) And Middle East (Me)P. G. CONAGHAN, V. STRAND, A. DEODHAR, E. SULLIVAN, S.BLACKBURN, H. TIAN, K. GANDHI, S. M. JUGL, R. ALTEN

ABS274 Appropriate Ankylosing Spondylitis (As) Treatment Is Delayed For Years: Multi-National Survey Results Including Asia Pacific (Apac) And Middle East (Me)V. STRAND, P. G. CONAGHAN, R. ALTEN, E. SULLIVAN, S.BLACKBURN, H. TIAN, K. GANDHI, S. M. JUGL, A. DEODHAR

ABS278 Validity of Ultrasonogaphy versus MRI in diagnosis of shoulder pain in RA patientsM. ABDEL ZAHER, S. THARWAT, A. ABDEL KHALEK, A.ABDELSALAM

61



ABS260 Prevalence of Fibromyalgia in Infertile WomenN. A. JASSIM, R. A. SHAKIR, A. H. BADR, J. A. HUMMADI

ABS263 Delayed Presentation of Pulmonary Arterial Hypertension in Saudi Patients with Systemic Sclerosis; a Multicenter Retrospective StudyA. A. ALHIJJI, H. A. ALOTAIR, M. IDREES, S. SALEEMI, A. ALTOUKHI,F. ALDURAIBI, Mohammed A. OMAIR

ABS264 Clinical and Laboratory Manifestations of Antiphospholipid Syndrome Among Saudi Patients: Examining the Applicability of Sapporo CriteriaF. AL-QAHTANI, A. S. ARFAJ, S. ASFAR, M. A. OMAIR

ABS266 Lupus Nephritis Induction in Saudi Arabia; a Multicenter Retrospective StudyA. A. ALHIJJI, A. ALSWAIDA, H. KFOURI, A. ALOUN, H. HALABI, A.AL-BEITY,H. ALRAYES, S. ABDULAZIZ, A. ASIRI, F. A. ALSHAHRANI,H. S. ALQAHTANI, M. SOMAILY, H. ABOUSAREE, M. A. OMAIR

ABS293 Bryophyllum pinnatum depletes B cells dependent to NF-kB p65 in pristane induced lupus mice modelE. S. DEWI, T. W. I. DANTARA, K. HANDONO, NURDIANA, M. Z.PRATAMA

ABS290 Anti-Fractalkine Monoclonal Antibody Ameliorated Collagen-Induced Arthritis Accompanied by Reduced Migration of Osteoclast Precursor Cells N. ISHII, K. HOSHINO-NEGISHI, M. OHKURO, T. NAKATANI, W.IKEDA, Y. KUBOI,T. YAMAUCHI, N. YASUDA1, T. IMAI

ABS297 Nitric Oxide Accelerates Cell Proliferation by Preventing BIK Expression in Rheumatoid Arthritis SynoviumT. UEHA, Y. SAKAI, K. SUZUKI, M. YASUDA, K. FUKUDA, H.NISHIMOTO, S. HAYASHI,Y. MIURA, R. KURODA, A.HASHIRAMOTO

ABS294 Discover new function of cold compress as stress treatment for patients with systemic lupus erythematosus: development of basic nursing therapyTBA

ABS300 Patterns of Organ Involvement in SLE and Their Outcome with Standard Treatment: a Real Life Experience in a Lupus ClinicE. S. DEWI, SOEMARDINI, I. S. RINI

ABS307 Clinical Evaluation of Lupus Skin lesions and Skin infections in Systemic Lupus Erythematosus PatientsM. Z. HAIDER, M. N. ISLAM, A. ASADUZZAMAN, N. FERDOUS, J.J. H. RASKER

62



ABS310 Frequency of HLA-B and HLA-C alleles in patients with psoriasis, psoriatic arthritis and undifferentiated spondyloarthritisS. AHMED, S. A. HAQ, T. ISLAM, A. T. M. ASADUZZAMAN

ABS312 Short-term and long-term outcomes of biosimilar infliximab (BOW015) treatment in rheumatoid arthritis– A single-centre retrospective study S. N. AMIN, A. KAPADIA, M. SHAMIL

ABS289 Radiologic Features in Symptomatic/Asymptomatic Heels with Ankylosing SpondylitisI.-H. SUNG, T.-H. KIM, J. K. LEE, H.-K. SUNG, B.-H. KIM, Y. S.SONG

ABS295 Empowerment of Lupus support group members as health cadres to increase the community knowledge in an effort to raise the public awareness about LupusE. S. DEWI, K. HANDONO, H. KALIM, C. S. WAHONO, M.FATHONI

ABS299 Diagnostic Value of Color Doppler Ultrasonic for gouty arthritis in China : A Meta-AnalysisH. YEFEI, O. JIAYONG, G. JIERUO

ABS309 Age and quality of life among rheumatoid arthritis patients treated with biologic agentsN. OGURO, N. YAJIMA, Y. MIWA

ABS298 Factors associated with Severity of Pain and Functional impairment in Hand Osteoarthritis: From NAGARAM cohortY. S. SUH, H.-O. KIM, Y.-H. CHEON, M.-K. HAN, S.-I. LEE

ABS306 Axial and non-axial subtype of SAPHO syndrome: A single center cohort studyY. CAO, C. LI, N.WU, Z. GUO, Z. GU, X. WU, S. YUAN, Y.ZHAO, W. TAO, X. SUN, Z. DONG, W. ZHANG

ABS296 Comparing treatment indication by FRAX and BMD alone in rheumatic patients on long-term glucocorticoid in Hong KongS. L. LAU, L.-S. TAM, THE HONG KONG GIOP STUDY GROUP

ABS319 Association of mitochondrial DNA copy number with disease activity in rheumatoid arthritis D. SHEEN, J. YOO, S. A. KIM, M.-K. LIM

ABS324 Polyamine patterns of patients with systemic lupus erythematosusJ.-Y. JUNG, H.-A. KIM, T. H. SHIN, W.-Y. BAEK, K.-S. RYU, G. LEE,M.-J. PAIK, C.-H. SUH

ABS327 Gut hormones in patients with psoriasis &/or psoriatic arthritisC.-Y. TSAI, H.-T. LIAO, C.-T. CHOU, W.-S. CHEN

63



ABS325 The free fatty acid profiles in patients with systemic lupus erythematosusJ.-Y. JUNG, H.-A. KIM, T. H. SHIN, W.-Y. BAEK, K.-S. RYU, G. LEE,M.-J. PAIK, C.-H. SUH

ABS333 TGF-beta3-producing LAG3+ regulatory T cells pulmonary fibrosis through inhibiting fibroblast-myofibroblast transition L. H. BO, W. C. CHEN, Z. XIAO

ABS316 Translation, cross-cultural adaptation and validation of the Pain Catastrophizing Scale (PCS) into Bengali in patients with chronic non-malignant musculoskeletal painM. S. M. MAJUMDER, S. AHMED, S. A. HAQ, Md. NAHIDUZZAMANESHAZZAD, A. T. HASAN

ABS317 Efficacy of pamidronate treatment in patients with synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome: a single-arm clinical trialC. LI, Y. ZHAO, N.WU, Z. DONG, Z. WU

ABS322 The Overlap of RA and Spondyloarthritis is Rarely Recognized: Management may not Differ but a Research Opportunity is lostA. KIRAN, A. VENUGOPALAN, N. KULKARNI, M. ABRAHAM, C. ARVIND

ABS323 Cluster analysis of systemic lupus erythematosus by using laboratory dataJ.-Y. JUNG, W.-Y. BAEK, K.-S. RYU, H.-Y. LEE, H.-A. KIM, J. BYUN, D.YOON, C.-H. SUH

ABS326 An analysis of the clinical features of malignancy in patients with connective tissue diseases associated interstitial lung diseaseTBA

ABS328 Macrophage Activation Syndrome in Dengue FeverS. SANDEEP, S. SELVA, D. ARUN, S. JYOTHI, M. G. K. PILLAI

ABS329 Breast Cancer with Paraneoplastic Syndrome in a male patient: A case reportTBA

ABS335 Pregnancy Outcome in Rheumatoid Arthritis (RA) : A Retrospective Study At Hospital Sultan Ismail (HSI), Malaysia.E. L. LAI, Y. L. LOH

ABS318 F-18 FDG PET/CT in 26 patients with SAPHO syndrome: a new vision with clinical and bone scintigraphy correlationC. LI, X. SUN, Y. CAO, H. JING, Z. DONG, W. ZHANG

ABS320 Itolizumab for the Treatment of Psoriatic Arthritis: Yet Another Promising Biologic DMARDC. ARVIND, A. KIRAN, M. ABRAHAM, N. KULKARNI, K. TOKTAM, S.MANJIT

64



ABS321 Indian (Asian) Patients and Young Women in Particular Suffer More Than their Dutch Counterparts: Study Based on METEOR International Rheumatoid Arthritis (RA) DatabaseC. ARVIND, S. MANJIT, S. ANNE, K. TOKTAM, A.VENUGOPALAN, T. HUIZINGA

ABS345 Role of maintenance therapy after induction in patients with scleroderma ILD:Results of 5 year observational studyP. SHENOY, B. ALIAS, K. NALIANDA, S. AHMED, S. SREENATH

ABS349 The profile investigating of rheumatoid arthritis (RA) patients who received adalimmab therapy in AORA (Akita Orthopedic Group on RA)TBA

ABS353 Cytomegalovirus Infection In Granulomatous With Polyangiitis (Gpa) TBA

ABS354 Cytomegalovirus infection complicating Granulomatous with polyangiitis S. M. A. RAHIM, S. S. CHNG, H. BAHARUDDIN

ABS355 Febuxostat In Gout – A Single Rheumatology Centre ExperienceS. M. A. RAHIM, N. ZAINUDIN, I. S. LAU, M. M. ZAIN, H.BAHARUDDIN

ABS371 A case report:Tumor-induced Osteomalacia caused by elevated FGF23 secretionK. V. HUYNH

ABS351 Serum Levels of Prolactin and Sex Hormones in Scleroderma Patients and Their Correlation with Disease Duration and Clinical Manifestations E. ESMAEILZADEH, M. A. NAZARINIA, F. YAVARI, M. SHAMS, E.KAMALI-SARVESTANI

ABS352 52-week Drug Survival of Subcutaneous Anti-TNF and Non-TNF Biologic Agents for Elderly Rheumatoid Arthritis PatientsH. KATAOKA, M. KONDO, M. MUKAI

ABS356 Real-life patient characteristics and treatment assessments following clinical use of biosimilar adalimumab (Exemptia™) in patients with various inflammatory arthritis conditions. A. BADIKA

ABS357 Identification of knee osteoarthritis patients in the claims database H.-R. PARK, S.-K. CHO, S. G. IM, S.-Y. JUNG, E.-J. JANG, Y.-K. SUNG

ABS359 Prevalence of Secondary Sjögren's Syndrome in Patients with Rheumatoid Arthritis S.-K. CHO, SJ CHA, H.-R. PARK, Y.-K. SUNG

65



ABS362 Disease activity in patients with SAPHO Syndrome: a correlation of clinical and magnetic resonance imaging fingdingsZ. GU, Y. CAO, Y. Z. YUAN, W. TAO, C. LI

ABS358 Characteristics of Secondary Sjogren’s Syndrome with Rheumatoid Arthritis Compared to Primary Sjogren’s SyndromeS. J. CHA, S.-K. CHO, D. KIM, H.-R. PARK, S. W. NAM, H. W.LIM, S.-J. SHIN, K. S. JANG,K.-G. HWANG, Y. Y. CHOI, Y.-K.SUNG

ABS372 Demographic and serologic profile of Palindromic Rheumatism patients versus those with established Rheumatoid arthritis. S. PANDYA, R. SOLANKI, T. PARIKH

ABS373 Demographic and immunologic profile of patients with Primary Sjogren’s and application of ESSPRI and ESSDAI to theseS. PANDYA, R. SOLANKI, T. PARIKH

ABS374 Is 100mg Rituximab good enough in RA ?N. JAIN, S. PANDYA, P. SRIVASTAVA

ABS375 To study drug prescription patterns, adherence and quality of life over a 3 month period in patients with RA (Rheumatoid arthritis) H. RAJGADHI, S. PANDYA, P. SHRIVASTAVA, S. MALHOTRA

ABS380 Clinical Outcomes and Characteristics of SSc Patients with Interstitial Lung Disease and Pulmonary Arterial Hypertension in the Scleroderma Cohort Singapore N. MARIA, S. E. SAFFARI, K. S.M. YU, C. GRACE, T. G. GEE, L. W.GIAP, S. AMELIA, L. ANITA, N. S. CHENG, L. A. H. LING

ABS381 Subclavian Steal Syndrome Secondary To Takayasu Aorto-Arteritis- Successfully Managed With Carotid AngioplastyTBA

ABS382 Adult Onset Still’s disease- Study of series of 10 cases experience from tertiary care rheumatology units.A. K. GUPTA

ABS388 Clinical manifestations and incidence of cardiac involvement in Thai patients with early systemic sclerosis (SSc): comparison between early-versus late-onset SScS. WANGKAEW, P. PHIRIYAKRIT, V. SAWANGDUAN, N.PRASERTWITTAYAKIJ,J. EUATHRONGCHIT

66



ABS391 Pharmacovigilance as a tool for understanding rheumatic disease pathophysiology: opportunities and challenges of ‘bedside-to-bench’ discovery with oncological immune checkpoint inhibitorsD. LIEW, J. LEUNG, B. LIU, R. BUCHANAN

ABS392 The uptake of rheumatological pharmacogenomic testing across specialty units at an Australian academic hospitalD. LIEW, M. NGUYEN, J. BOOTH, R. BUCHANAN

ABS396 Effect Of Baseline Bmi On Efficacy And Safety Of Filgotinib In Rheumatoid Arthritis Patients: Post-Hoc Analysis From Phase 2B StudyY. TANAKA, A. VAN DER AA, C. JAMOUL, C. TASSET, P. HARRISON,R. WESTHOVENS

ABS397 Clinical significance of serum caspase-1 level in inflammatory arthritides.H.-J. JEONG, C.-N. SON, J.-M. KIM, S.-H. KIM

ABS399 Probiotic Supplementation And Its Effect On Disease Activity In Rheumatoid Arthritis: A Systematic Review And Meta-AnalysisE. M. M. DEJORAS, P. P. M. REMALANTE, A.-T. M. SANTIAGO

ABS402 Clinical results of THA and TKA during the use of biologics in patients with rheumatoid arthritisN. KONISHI, T. KASHIWAGURA, M. KOBAYASJI, O. SAKURABA, Y.SUGIMURA,N. MIYAKOSHI, Y. SHIMADA

ABS385 Human Mesenchymal Stem Cells Induce the Expression of CD4+ CD25+ FoxP3+ Programmed Cell Death-1+ Regulatory T Cells from CD4+T cellsC. H. MUN, Y. D. SHIN, M. KIM, Y.-B. PARK

ABS398 Aberrant expression of CaMK4 in CD4 positive T cells predicts poor response to treatment in patients with active rheumatoid arthritisT. KOGA, T. SATO, M. UMEDA, S. FUKUI, A. NISHINO, S.-Y.KAWASHIRI, N. IWAMOTO, K. ICHINOSE, M. TAMAI, T.ORIGUCHI, H. NAKAMURA, A. KAWAKAMI

ABS400 The imbalance of Th17 and Treg cells in patients with active synovitis, acne, pustulosis, hyperostosis, osteiti (SAPHO) syndromeTBA

ABS401 Serum levels of cytokines and RANKL/OPG in synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) SyndromeS. ZHANG, S. ZHANG, L. LI, W. ZHANG, Z. DONG, W ZHANG,C. LI

ABS410 The complications of the plasma exchange and the immune adsorption in treating 110 patients with rheumatoid disease in chinaX. I. ZHANG, Z. LIN, J. QI, Q. LV, M. YANG, O. U. JIN, L. FANG, Z. LIAO,D. LIN, J. GU

67



ABS411 The side effects of the plasma exchange and the immune adsorption in treating 110 patients with rheumatoid disease in chinaX. I. ZHANG, Z. LIN, J. QI, Q. LV, M. YANG, O. U. JIN, L. FANG, Z. LIAO,D. LIN, J. GU

ABS425 Use of Lower Dose Etanercept and Risk of Tuberculosis in Spondylo-Arthritis Patients-Study from a Tuberculosis Endemic CountryN. ISLAM, A. U. ZAMAN, F. B. NAZRUL, N. FERDOUS, Y. MOON,F. H. RAHMAN,T. SHARMIN, J. J. H. RASKER

ABS426 Prospective study of patients with Spondyloarthritis in South India.T. DHIVYA, S. NALLASIVAN

ABS427 Diversity Of Rheumatology Patients In A Newly Established Medical College Hospital In South India- Category 19S.NALLASIVAN, Y.VISHALINI, J.RAJMA, J.BALAJI, V.RAMASAMY

ABS430 Clinical And Immunological Profile Of Patients With Sle And Special Focus On Lupus Nephritis In A Teaching Hospital – Category 7Y. RAVINDRAN, A. KESAV, T. V. SAGAR, A. SHARMA, S NALLASIVAN

ABS432 Assessment Of Clinical Response And Drug Discontinuation For Iv Tocilizumab In Patients With Rheumatoid ArthritisM. M. NOH, N. S. SHAHRIL, L. M. NOR

ABS434 Efficacy and Safety of Adalimumab (ADA) in Patients With Non-Radiographic Axial Spondyloarthritis (nr-axSpA): Open-Label Period Results from the ABILITY-3 StudyTBA

ABS409 Predisposing Factors of Tuberculosis Infection in Systemic Lupus Erythematosus PatientsA. ARIANE, I. DAMARA, S. ANGGORO, B. SETYOHADI

ABS418 Association Of Anticardiolipin Antibody And Systemic Lupus Erythromatosus NephropathyC. W. HMONE, M. NAING, W. WAI, L. ZAW, C. SOE

ABS422 Bone mineral density and bone turnover markers in elderly with hip fractureH. VU THI THANH, T. LE VIET, N. TRAN HONG, N. PHAM DANG, H.LE THU

ABS428 Biosimilars in Rheumatology-Real life data from South India- CAT 3/4/9S. NALLASIVAN

ABS433 Predictors of Remission at Week 12 in Patients With Non-Radiographic Axial Spondyloarthritis Receiving Open-Label Adalimumab Treatment in the ABILITY-3 StudyTBA

68



ABS435 Changes in hemoglobin levels upon treatment with Upadacitinib (ABT-494), a selective JAK-1 inhibitor, and relation to baseline C-reactive protein levelsV. STRAND, M. GENOVESE, J. KREMER, M. SCHIFF, Y. LI, J.SOKOLOVE

ABS419 Clinical profile of Takayasu’s arteritisT. T. YU, S. S. MYINT, W. WAI, L. ZAW, C. SOE

ABS420 Prevalence of SSc-ILD in Systemic sclerosis patientsW. WAI, L. ZAW, S. M. MOH, C. M. LWIN, C. SOE

ABS441 Study of the GDF5 and Asporin Gene Polymorphism in patients with Knee Osteoarthritis in Kurdish people comparison with control group TBA

ABS453 A Novel Gold Compound Ameliorates Murine Arthritis and Bone Erosion with Excellent Bio-Safety by Suppressing NF-kB Mediated Inflammation and Osteoclastogenesis Q. YUAN, X. GAO

ABS456 Methyl Gallate Inhibits Osteoclast Formation and Function through Suppressing the Akt and Btk-PLCy2-Ca2+ Signaling, and Prevents LPS-Induced Bone LossCH CHUNG, CH LEE, JM BAEK, J.-Y. KIM, SJ HONG, MS LEE

ABS454 IL-17A induced autophagy that the migration of rheumatoid arthritis fibroblast-like synoviocytes through down-regulation of mTORSang-Hyon KIM, Jihye BANG, Ji-Min KIM, Chang-Nam SON, Jin-Nyeong CHAE, Hye-Jin JEONG

ABS440 Rheumatoid hand: Can synovitis solely cause tendon rupture?TBA

ABS444 TBATBA

ABS449 Can spinal fracture in the patient with ankylosed spine be treated conservativelyTBA

ABS450 Do We Need Specific Diagnostic Criteria For Elderly-Onset Rheumatoid Arthritis?C. H. BAIMUKHAMEDOV

ABS455 Successful Treatment of pseudoseptic arthritis contained massive purulent fluid with Adalimumb In patient with Rheumatoid arthritisM. S. LEE, C. H. CHUNG, C. H. LEE, S. J. HONG

69



ABS458 Clinical And Ultrasound Prevalence Of Peripheral Enthesitis In An Algerian Cohort Of Spondyloarthritis A. HADDOUCHE, S. SLIMANI, S. HAID, S. BENCHEIKH, A.ABDESSEMED, N. BRAHIMI, A. LADJOUZE

ABS464 LEFT UPPER LIMB MONOPARESIS AND LEFT EYE PTOSIS DUE TO HERPES ZOSTER INFECTION IN A PATIENT WITH SYSTEMIC LUPUS ERYTHEMATOSUSTAN IJ, CH’NG SS, BAHARUDDIN H,

ABS436 Changes in C-Reactive Protein and Lipid Levels in Patients with Rheumatoid Arthritis treated with Upadacitinib (ABT-494), a Selective JAK-1 InhibitorM. NURMOHAMED, Y. ZHANG, J. H. LIN, H. S. CAMP

ABS437 Long-Term Efficacy and Safety of Adalimumab in the Ongoing Non-Infectious Open-label VISUAL-III study in Patients treated-with Placebo/Adalimumab in VISUAL-I/II trials J. T. ROSENBAUM, E. FORTIN, L. L. LIM, H. GOTO, N. HASHIDA, M.KRON, A. P. SONG,K. DOUGLAS, R. LANDEW E, S. PATHAI

ABS442 Prophylaxis of Acute Flares when Initiating Febuxostat for Chronic Gouty Arthritis in a Real-World Clinical SettingJ. YU

ABS451 GLUcocorticoids in Management of Adult Rheumatoid arthritis - Current prescribing practices and perceptions of physicians in India: GLUMAR surveyTBA

ABS459 Clinical versus ultrasound evaluation of peripheral enthesitis in a cohort of spondyloarthritesA. HADDOUCHE, S. SLIMANI, S. HAID, S. BENCHEIKH, A.ABDESSEMED, N. BRAHIMI, A. LADJOUZE

ABS461 Predictive factors for response to ultrasound-guided intra-articular glucocorticoids in knee osteoarthritisS. SLIMANI, A. AISSOUG, S. AOUIDANE, H. BOUNECER, H.MAKHLOUFI, A. LADJOUZE-REZIG

ABS462 Therapeutic drug monitoring of mycophenolic acid in patients with Lupus NephritisM. KONO, S. YASUDA, S. TANIMURA, S. SHIMAMURA, Y. FUJIEDA, M.KATO, K. OKU,T. BOHGAKI, O. AMENGUAL, T. ATSUMI

ABS463 Predominant pulmonary involvement in granulomatosis with polyangiitis H. BAHARUDDIN, M. A. M. ZIM, MARIAM, H. M. YUSOOF, M. M.ZAIN, S. S. CH’NG

ABS465 A rare case of asymptomatic lymphocytic interstitial pneumonia (LIP) with severe radiologic changes.H. BAHARUDDIN M. A. M. ZIM1, S. S. S. AFLAH, S. S. CH’NG

70



ABS443 Establishment and Validation of Prediction Nomogram for Liver Function Impairment in Gout treated with FebuxostatJ. YU

ABS467 Increased susceptibility of SLE-prone mice to Haemophilus influenzae infection was attributed to deficiency of innate immune responsesTBA

ABS468 Endothelial cell injury associated with lupus symptoms and atherosclerosis in ApoE-/- Faslgld C57BL/6 miceS. WANG, G. YAO, L. SUN

ABS485 MTORC1 phosphorylation in CXCR3+ memory B cells and its relevance to pathogenesis of rheumatoid arthritisS. IWATA, M. ZHANG, M. HAJIME, K. SAKATA, M. TORIGOE, Y.MIYAZAKI, N. OHKUBO, K. NAKANO, S. NAKAYAMADA, Y.TANAKA

ABS486 Lupus-prone SLAM haplotype exerts monocytosis and develops mixed connective tissue disease-like phenotype introduced by Yaa mutation.H. AMANO, K. NISHIKAWA, Q. LIN, S. KAWANO, K. YAMAJI, S.HIROSE, N. TAMURA

ABS469 Clinical significance of plasma Presepsin levels in patients with systemic lupus erythematosusS. TANIMURA, Y. FUJIEDA1, M. KONO, R. HISADA, E. SUGAWARA,H. NAKAMURA,K. OHMURA, S. SHIMAMURA, T. WATANABE, H.SHIDA, M. KATO, K. OKU, T. BOHGAKI, O. AMENGUAL, SYASUDA, T. ATSUMI

ABS471 Prevalence of Interstitial lung disease and its associations in a cohort of Rheumatoid arthritis.TBA

ABS472 Carotid Atherosclerosis is associated with compromised volumetric bone mineral density and microstructures in patients with inflammatory arthritisI. T. CHENG, Q. SHANG, E. K. LI, P. WONG, E. W. KUN, M LI1, T. K.LI, T. Y. ZHU,A. P.-W. LEE, L. QIN, L.-S. TAM

ABS473 Double blind study of combined IL-1Ra treatment with cartilage and synovial peptides of patients with acute rheumatoid arthritis. TBA

ABS475 Macrophage migration inhibitory factor and interleukin-8 in gouty arthritisH.-R. KIM1, K.-W. KIM1, B.-M. KIM1, K.-A. LEE1, H.-S. KIM2, S.-H. LEE1

71



ABS477 Higher Uric Acid Is Associated With A Lower Disease Activity In Rheumatoid Arthritis Patients: Results From The KRRD RegistryA. AL-HERZ, A. ALDEI, K. SALEH, A. AL-AWADHI, W. AL-KANDARI,E. HASAN,A. GHANEM, M. HUSSAIN, E. NAHAR, F. ABUTIBAN, A.ALENIZI, Y. ALI, H. ALHAJERI,S. HAYAT, A. KHADRAWY, A. FAZAL,K. MOKADDEM, A. ZAMAN, G. MAZLOUM,Y. BARTELLA, S.HAMED, R. ALSOUK, A. AL-SABER, KUWAIT REGISTRY FOR RHEUMATIC DISEASES (KRRD)

ABS478 High Uric Acid As A Risk Factor For Cardiovascular Diseases In Rheumatoid Arthritis Patients: Results From The KRRD RegistryA. AL-HERZ, A. ALDEI, K. SALEH, A. AL-AWADHI, W. AL-KANDARI,E. HASAN,A. GHANEM, M. HUSSAIN, E. NAHAR, F. ABUTIBAN, A.ALENIZI, Y. ALI, H. ALHAJERI, S. HAYAT, A. KHADRAWY, A. FAZAL,K. MOKADDEM, A. ZAMAN, G. MAZLOUM,Y. BARTELLA, S.HAMED, R. ALSOUK, A. AL-SABER, KUWAIT REGISTRY FOR RHEUMATIC DISEASES (KRRD)

ABS479 Rheumatoid Arthritis Patients Resistant To Biologic Therapy, Are They Different?: Results From The KRRD RegistryA. AL-HERZ, A. GHANEM, K. SALEH, A. AL-AWADHI, W. ALKANDARI, E. HASAN,M. HUSSAIN, E. NAHAR, F. ABUTIBAN, A.ALENIZI, Y. ALI, A. ALDEI, H. ALHAJERI,S. HAYAT, A. KHADRAWY,A. FAZAL, K. MOKADDEM, A. ZAMAN, G. MAZLOUM,Y. BARTELLA,S. HAMED, R. ALSOUK, A. AL-SABER, KUWAIT REGISTRY FOR RHEUMATIC DISEASES (KRRD)

ABS487 A World Outside VasculitisV. S. CHANDRAN, J SRIKANTH

ABS491 Meta-analysis: diagnostic accuracy of antibody against peptidylarginine deiminase 4 by ELISA for rheumatoid arthritisJ. REN, L. SUN, J. ZHAO

ABS492 Disease Characteristics and Change of Arthritis Activity According to Treatment in Hepatitis B Surface Antigen Positive Rheumatoid Arthritis PatientsY. EUN, I. Y. KIM, H. KIM, J. LEE, E.-M. KOH, H.-S. CHA

ABS493 Sexual dysfunctions and mental health status in males with Behcet disease compared with healthy peopleH. KAVANDI, P. EBRAHIMI, A. SHAFIEE-KANDJANI, D. KAVANDI, A.KHABBAZI

ABS494 Takayasue arteritis in a cohort of patients in IranH. KAVANDI, M. SOROOSH, A. KHABBAZI

72



ABS495 Association of MECP2 gene single nucleotide polymorphisms with susceptibility to juvenile idiopathic arthritis patients in Iranian populationM. MAHMOUDI, E. HAMZEH, S. ASLANI, V. ZIAEI, S. POURSANI,N. REZAEI

ABS496 MECP2 gene single nucleotide polymorphisms in Iranian patients with juvenile systemic lupus erythematosusM. MAHMOUDI, S. ASLANI, E. HAMZEH, V. ZIAEI, S. POURSANI,M. H. NICKNAM, N. REZAEI

ABS498 Exploring of IRF7 gene expression and methylation of its promoter region in peripheral blood mononuclear cells patients with systemic sclerosisR. REZAEI, M. MAHMOUDI, F. GHARIBDOOST, H. KAVOSI, N.DASHTI, V. IMENI, A. JAMSHIDI, S. ASLANI, S. MOSTAFAEI, M.VODJGANI2

ABS499 Role Of Il-6,Ifn-A In Sle And Their Corelation With Sledai & Slicc Acr Damage Index In An Eastern Indian Cohort M. K. PARIDA, S. S. PATTANAIK, B. K. DAS

ABS509 The Impact Of High-Dose Narrowband Ultraviolet A1 On Dermal Fibrosis InPre-Established, Bleomycin-Induced Mouse Model Of SclerodermaD. KARPEC, R. RUDYS, L. LEONAVICIENE, Z. MACKIEWICZ, RBRADUNAITE, G KIRDAITE, R. RUGIENE, A. VENALIS

ABS497 The expression of Purinergic signaling molecules in macrophages from Patients with Ankylosing SpondylitisM. AKHTARI, S. J. ZARGAR, M. VOJDANIAN, A. JAMSHIDI, A.REZAEIMANESH,M. T. PAILIZGIR, M. MAHMOUDI

ABS520 Study Of In Vitro T Cell/Myotube Interaction Disclosed Invasive And Cytotoxic Nature Of Cd8+ Cells Enclosed In The Muscle Cells.M KAMIYA, N KIMURA, A TAKAMURA, F MIZOGUCHI, K KAWAHATA, H KOHSAKA

ABS510 Clinical Characteristics and Outcome of Vasculitides at Patan Hospital, NepalTBA

ABS521 Role Of Calprotectin In Assessing Mucosal Inflammation In Gut Related SpondyloarthritisA. PARHI, N. PRADHAN, M. MEHER, S. SWAROOP, M. PARIDA, B. K.DAS

ABS522 Clinical Characteristics of Immune Checkpoint Inhibitors-Induced Myositis: A Case Report and Literature ReviewH. KADOTA, T. GONO, Y. SHIRAI, Y. OKAZAKI, M. TAKENO, M.KUWANA

ABS524 Bertolotti’ S Syndrome : The Masquerade Of Low Back Pain H. C. HONG, S. V. PILLAI, S. C. GUN

73



ABS517 Role Of Serum Procalcitonin And C-Reactive Protein In Differentiating Bacterial Infection From Disease Activity In SleS. SAHOO, B. D. GOMANGO, K. K. GOEL, M. PARIDA, R. TRIPATHY, B.K. DAS

ABS534 Escalating Dose Of Self- Dsdna Antigen Suppress Immune Activation In Prostane -Induced Lupus Mice K. HANDONO, N. NURDIANA, S. PURANTO, K. D. HARTANTI, S.ARIFIN, H. KALIM

ABS544 Association Of Genes About G-Protein Coupled Receptors And Ankylosing Spondylitis In Chinese Han Q. LV, J. QI, X. WU, J. GU

ABS546 Region Of Chromosome 16 Associated With Genetic Susceptibility Of Ankylosing Spondylitis: Exome Sequencing And Validation Study Of A Family Q. LV, J. QI, X. WU, X. ZHENG, Y. JIANG, J. GU

ABS529 Treat To Target In Gout: How Well Is It Achieved At A Private Tertiary Medical Center In Malaysia?C. S. MAY, B. CHEAH, T. L. YIN, N. Y. SHUEN, C. W. ERN

ABS530 Decreased inflammasome activation in healthy subjects treated with benzbromarone.TBA

ABS531 Fever, Rash, Oral ulcers and Bilateral Uveitis as an Initial Presentation of Behçet’s SyndromeN. MUSTAFA, M. MUSGRAVE, H. NOFAL

ABS535 Efficacy and safety of mizoribine in active rheumatoid arthritis patients unsuccessfuLly treated with DMARDs: open label, multicenter, randomized studyB. Y. KIM, S.-J. HONG, H.-S. KIM, Y. I. SEO, D. SHEEN, K. M. SON,K. W. MOON, S. S. KIM

ABS536 Ostial Left Main Coronary Artery Stenting of a Patient with Takayasu Arteritis: a Case Report and a Review of Related LiteratureM. TIONGSON, M. MURILLA, J. AHERRERA, M. BALABAGNO, C.AGUSTIN, E. DEJORAS, P. REMALANTE, E. SALIDO, M. ABOLA, E.ALAJAR, E. SISON

ABS540 The addition of Curcuma Xanthorriza on Vitamin D3 supplementation did not improve fatigue and cytokines (IL-6 and TGF-B1 ) in Systemic Lupus Erythematosus (SLE) Patients with Hypovitaminosis D C.SINGGIH WAHONO, I SAVERIA, H KALIM, K HANDONO

ABS542 Effect of Curcuma Xanthorrhiza addition In Systemic Lupus Erythematosus (SLE) Patients with Hypovitamin D which were given Vitamin D3 towards SLEDAI (SLE Disease Activity Index), IL-6 and TGF- B1 serum C. S WAHONO, C. D. SETYORINI, H. KALIM, K. HANDONO

74



ABS545 A Retrospective Analysis Of Medicine Use In 2755 Cases Of Spondylarthritis Q. LV, J. QI, L. TU, Y. JIANG, J. GU

ABS547 Prevalence of malnutrition in rheumatology patients: evaluation of nutritional status and prognosis.Q. LV, J. QI, Y. JIANG, J. GU

ABS548 Analysis of autoantibody spectrum of neuromyelitis opticaQ. LV, J. QI, X. ZHANG, M. QIU, J. GU

ABS551 An Unusual Case Of Sle Presenting With Multiple Sequential Manifestations Of NpsleM. R. BEHERA, M. PARIDA, B. K. DAS

ABS555 Rheumatoid Arthritis, A Diagnostic Challenge in Developing World of PakistanTBA

ABS526 Prevalence of arterial stiffness evaluating by cardio-ankle vascular index (CAVI) in Thai rheumatoid arthritis patients comparing with sex-matched controlsP. TIRASATHIT, D. AIEWRUANGSURAT

ABS533 Treatment response to a combination of Methotrexate and Sulfasalazine in Axial Spondyloarthritis in a resource limited real world clinical setting A. GANAPATI, S. PULIKOOL, B. ANTONISAMY, D. DANDA

ABS541 Effect Of Curcuma Xanthorrhiza Addition In Vitamin D3 Administration Towards Proteinuria, Serum Anti-Dsdna And Il-17 Levels On Systemic Lupus Erythematosus (Sle) Patients With Hypovitaminosis DC. SINGGIH WAHONO, Z. D. WAHYUNI, H. KALIM, K. HANDONO

ABS543 Characteristics of Pulmonary Involvement in Thai Systemic SclerosisC. UNHAPIPATPONG, C. FOOCHAROEN, S. SUWANNAROJ, P.TUMSATAN,R. NANAGARA, A. MAHAKKANUKRAUH

ABS549 Analysis of low-density lipoprotein subclass in patients with gout.Q. LV, J.QI, Y. HUANG, Z. CHEN, X. ZHANG, J. GU

ABS585 Antibodies to AHNAK1 is a novel autoantibodies specifically recognized in patients with systemic lupus erythematosusK. NOZAWA, K. DOE, Y. TAKASAKI, K. YAMAJI, N. TAMURA

ABS557 Rituximab therapy for refractory rapidly progressive interstitial lung disease related to anti-MDA-5 antibody-positive amyopathic dermatomyositisTBA

75



ABS559 Immunoabsorption plasma pheresis (IAPP) therapy is effective for Human papillomavirus vaccination-Associated Neuro-immunopathic Syndrome (HANS)TBA

ABS571 The frequency of low bone mineral density: In ankylosing spondylitis and rheumatoid arthritis patients K. R. SIGDEL

ABS572 Clinical features and treatment of the SAPHO syndrome Y. ISHIHARA, T. TOMITA, K. NISHIOKA

ABS581 Assessment of positive psychological well being in patients with rheumatic diseases and their comparison with control populationTBA

ABS562 Infliximab is effective in the treatment of rheumatoid arthritis regardless of body mass index: Post-hoc analysis of PLANETRA D. H. YOO, W. PARK, S. C. SHIM, C. H. SUH, S. J. LEE, S. Y. LEE, S.G. LEE, J.H. SUH

ABS563 Comparison of Pamidronate and Thalidomide in the Treatment of Refractory Axial Spondyloarthritis: An Open Label Randomized Clinical TrialTBA

ABS564 Diagnostic delay is associated with education level and worse outcomes in Chinese Ankylosing SpondylitisX. ZHENG, Z. CHEN, X. WU, H. LI, Y. XIE, J. WU, J. OU, R. YUAN, S.CAO, Q. WEI, J. GU

ABS567 Clinical significance of urate deposition in tendon: a dual-energy CT studyH. KIM, Y. EUN, I. Y. KIM, J. LEE, E.-M. KOH, H.-S. CHA

ABS569 Correlation between physical examination and synovitis on MRI in patients with rheumatoid arthritis before and after biological treatment. Y. KUKIDA, A. KASAHARA, T. SENO, T. INOUE, R. SAGAWA, T. KIDA, A.NAKABAYASHI, H. NAGAHARA, K. MURAKAMI, M. KOHNO, Y.KAWAHITO

ABS573 Outcomes of hospitalizations among patients with Systemic Lupus Erythematosus in a tertiarygovernment hospital in the PhilippinesJ. E. C. QUILISADIO, E. O. SALIDO, C. R. P. PAGADUAN, A. Q.URBANO

ABS574 Achievement of target serum urate level among patients with Gout in a tertiary government hospital in the PhilippinesJ. E. C. QUILISADIO, E. O. SALIDO, E. G. PENSERGA, G. M. D.GARCIA

76



ABS578 Maternal And Fetal Outcomes In Lupus Pregnancies In A South Indian Tertiary Care HospitalH MYLAVARAPU, D PONNURU, P DEVARASETTI, IRV PRASAD, L RAJASEKHAR

ABS579 Study of prevalence of comorbidities of hyperuricemia in Southern ChinaZ.-N. CHEN, Y. HUANG, S.-Z. HE, J. LIANG, X. PENG, J.-W. YU, W.ZHANG, S.-X. CHEN, Y.-M. LIN, Z. LIAO, J.OU, J.WU, X. L. XIE, X.ZHENG, X.WU, X.-W. LI, Q.-Y. CHEN, J.-R. GU P. RAJAVARAPU, C. KODISHALA, P. K. DEVARASETTI, I. R.VARAPRASAD, L. RAJASEKHAR

ABS566 Myocarditis In Takayasu Arteritis: Angiographic Association And OutcomeP. RAJAVARAPU, C. KODISHALA, P. K. DEVARASETTI, I. R.VARAPRASAD, L. RAJASEKHAR

ABS588 Study of Clinical Profile in Systemic Sclerosis Patients and Correlation of Pulmonary Function and Interstitial Lung DiseaseU. AGGARWAL, G. PANGTEY, T. GARG, P. ABBEY

ABS591 Bryophyllum pinnatum repairs nephritis, albuminuria, autoantibody production, and modulates adaptive immune system components in pristane-induced lupus mice modelE. S. DEWI, K. HANDONO, NURDIANA, U. KALSUM, H. KALIM

ABS592 Risk factors associated with osteoporosis in patients attending Rheumatology clinics, in a tertiary care hospitalTBA

ABS560 Reduced atherosclerosis in mice with conditional deletion of Spleen tyrosine kinaseTBA

ABS594 Effectiveness of joint-preserving surgery in rheumatoid hand N. NAKAGAWA, A. UEFUJI, T. HARADA, H. TAKAYAMA, K. AOKI, K.KISHIMOTO

ABS386 Characterization of Clinical Phenotype of Patients With Non-radiographic Axial Spondyloarthritis According to ASAS Classification Criteria in the ABILITY-3 StudyTBA

ABS484 The clinical outcomes of asymptomatic cardiac involvement in systemic sclerosis patients after 2-year follow up (extended study)B. PUSSADHAMMA, C. FOOCHAROEN, A. MAHAKKANUKRAUH, S.SUWANNAROJ, R. NANAGARA

ABS025 The Association Of Serum Pyridinoline With Radiographic Joint Erosions In Rheumatoid ArthritisS. RAJALINGHAM, N. H. A. M. MATARDIAH, R. SRIDHARAN,A. WAHAB

ABS194 The decision of a lower limb alignment by some measuring methods on radiographs in pre- and post- total knee arthroplastyTBA

THE NEXT GENERATION DMARD ISMAKING IT’S PRESENCE KNOWN 4

XELJANZ® is recommended in RA after failure of csDMARDs in the 2016 EULAR recommendations for the management of RA†2

XELJANZ™ 5 mg Abbreviated Prescribing Information:

WARNING: SERIOUS INFECTIONS AND MALIGNANCYSERIOUS INFECTIONS : Patients treated with XELJANZ™ are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. If a serious infection develops, interrupt XELJANZ™ until the infection is controlled. Reported infections include: Active tuberculosis, which may present with pulmonary or extra pulmonary disease. Patients should be tested for latent tuberculosis before XELJANZ™ use and during therapy. Treatment for latent infection should be initiated prior to XELJANZ™ use. Invasive fungal infections, including cryptococcosis and pneumocystosis. Patients with invasive fungal infections may present with disseminated, rather than localized, disease. Bacterial, viral, and other infections due to opportunistic pathogens. The risks and benefits of treatment with XELJANZ™ should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection. Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with XELJANZ™, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy MALIGNANCIES : Lymphoma and other malignancies have been observed in patients treated with XELJANZ™. Epstein Barr Virus- associated post-transplant lymphoproliferative disorder has been observed at an increased rate in renal transplant patients treated with XELJANZ™ and concomitant immunosuppressive medications.

Presentation: Xeljanz™ 5 mg is supplied for oral administration (equivalent to 8 mg tofacitinib citrate) white round, immediate-release film-coated tablet, debossed with “Pfizer” on one side, and “JKI 5” on the other side. Therapeutic indications: Rheumatoid arthritis: XELJANZ™ (tofacitinib) is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. It may be used as monotherapy or in combination with methotrexate or other nonbiologic disease-modifying antirheumatic drugs (DMARDs). XELJANZ™ should not be used in combination with biologic DMARDs or with potent immunosuppressants such as azathioprine and cyclosporine. Dosage and Method of Administration: XELJANZ™ may be used as monotherapy or in combination with methotrexate or other nonbiologic disease modifying antirheumatic drugs (DMARDs). The recommended dose of XELJANZ ™ is 5 mg twice daily. It is recommended that XELJANZ not be initiated in patients with an absolute lymphocyte count less than 500 cells/mm3, an absolute neutrophil count (ANC) less than 1000 cells/mm3 or who have hemoglobin levels less than 9 g/dL. Avoid use of XELJANZ if a patient develops a serious infection until the infection is controlled. XELJANZ™ dosage should be reduced to 5 mg once daily in patients: with moderate or severe renal insufficiency, with moderate hepatic impairment. Use of XELJANZ in patients with severe hepatic impairment is not recommended, receiving potent inhibitors of Cytochrome P450 3A4 (CYP3A4) (e.g., ketoconazole), receiving one or more concomitant medications that result in both moderate inhibition of CYP3A4 and potent inhibition of CYP2C19 (e.g., fluconazole). Co administration of potent inducers of CYP3A4 with XELJANZ may result in loss of or reduced clinical response. Contraindications: Known hypersensitivity to tofacitininb or to any of the excipients Special warnings and precautions for use: Serious Infections: Serious and sometimes fatal infections due to bacterial, mycobacterial, invasive fungal, viral, or other opportunistic pathogens have been reported in rheumatoid arthritis patients receiving XELJANZ™. XELJANZ™ should not be initiated in patients with an active serious infection, including localized infections. The risks and benefits of treatment should be considered prior to initiating XELJANZ™ in patients: with chronic or recurrent infection , who have been exposed to tuberculosis, with a history of a serious or an opportunistic infection, who have resided or traveled in areas of endemic tuberculosis or endemic mycoses; or with underlying conditions that may predispose them to infection. In the seven controlled trials, during the 0 to 3 months exposure, tuberculosis was not reported in patients who received placebo, 5 mg twice daily of XELJANZ, or 10 mg twice daily of XELJANZ. Screening for viral hepatitis should be performed in accordance with clinical guidelines before starting therapy with XELJANZ. Malignancy and Lymphoproliferative Disorder: Consider the risks and benefits of XELJANZ™ treatment prior to initiating therapy in patients with a known malignancy other than a successfully treated non-melanoma skin cancer (NMSC) or when considering continuing XELJANZ™ in patients who develop a malignancy. Non-Melanoma Skin Cancer: Non-melanoma skin cancers (NMSCs) have been reported in patients treated with XELJANZ. Periodic skin examination is recommended for patients who are at increased risk for skin cancer. Gastrointestinal Perforations: Although the role of JAK inhibition in these events is not known, XELJANZ™ should be used with caution in patients who may be at increased risk for gastrointestinal perforation (e.g., patients with a history of diverticulitis). Patients presenting with new onset abdominal symptoms should be evaluated promptly for early identification of gastrointestinal perforation. Laboratory abnormalities: Lymphocyte abnormalities Treatment with XELJANZ™ was associated with initial lymphocytosis at one month of exposure followed by a gradual decrease in mean absolute lymphocyte counts below the baseline of approximately 10% during 12 months of therapy. Lymphocyte counts less than 500 cells/mm3 were associated with an increase incidence of treated and serious infections Neutropenia:Treatment with XELJANZ™ was associated with an increased incidence of neutropenia (less than 2000 cells/mm3) compared to placebo . Anemia: Avoid initiation of XELJANZ™ treatment in patients with a low hemoglobin level (i.e. less than 9 g/dL). Treatment with XELJANZ™ should be interrupted in patients who develop hemoglobin levels less than 8 g/dL or whose hemoglobin level drops greater than 2 g/dL on treatment. Liver Enzymes elevations Treatment with XELJANZ™ was associated with an increased incidence of liver enzyme elevation compared to placebo. Most of these abnormalities occurred in studies with background DMARD (primarily methotrexate) therapy. Lipids elevations: Treatment with XELJANZ™ was associated with increases in lipid parameters including total cholesterol, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol. Maximum effects were generally observed within 6 weeks. The effect of these lipid parameter elevations on cardiovascular morbidity and mortality has not been determined. Vaccinations: No data are available on the response to vaccination or on the secondary transmission of infection by live vaccines to patients receiving XELJANZ™. Avoid use of Live vaccines concurrently with XELJANZ™. Special Population: Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. Nursing Mothers XELJANZ™ was secreted in milk of lactating rats. It is not known whether XELJANZ™ is excreted in human milk. A decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug for the mother. Pediatric Use: The safety and effectiveness of XELJANZ™ in pediatric patients have not been established. Geriatric Use: The frequency of serious infection among XELJANZ™ - treated subjects 65 years of age and older was higher than among those under the age of 65. As there is a higher incidence of infections in the elderly population in general, caution should be used when treating the elderly. Hepatic Impairment: No dose adjustment is required in patients with mild hepatic impairment. XELJANZ™ dose should be reduced to 5 mg once daily in patients with moderate hepatic impairment. XELJANZ treated patients with moderate hepatic impairment had greater tofacitinib levels than XELJANZ treated patients with normal hepatic function, higher blood levels may increase the risk of some adverse reactions. The safety and efficacy of XELJANZ™ have not been studied in patients with positive hepatitis B virus or hepatitis C virus serology. Renal Impairment: No dose adjustment is required in patients with mild renal impairment. XELJANZ™ dose should be reduced to 5 mg once daily in patients with moderate and severe renal impairment. In clinical trials, XELJANZ™ was not evaluated in rheumatoid arthritis patients with baseline creatinine clearance values (estimated by the Cockroft-Gault equation) less than 40 mL/min. Interaction with other medicinal products and other forms of interaction Potential for XELJANZ™ to Influence the pharmacokinetics (PK) of Other Drugs In vitro studies indicate that XELJANZ™ does not significantly inhibit or induce the activity of the major human drug-metabolizing CYPs (CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4) at concentrations exceeding 185 times the steady state Cmax of a 5 mg twice daily dose. Potential for Other Drugs to Influence the pharmacokinetics (PK) of XELJANZ™: Since XELJANZ™ is metabolized by CYP3A4, interaction with drugs that inhibit or induce CYP3A4 is likely. Inhibitors of CYP2C19 alone or P-glycoprotein are unlikely to substantially alter the PK of XELJANZ™. Undesirable effects: The most commonly reported adverse reactions during the first 3 months in controlled clinical trials (occurring in greater than or equal to 2% of patients treated with XELJANZ™ monotherapy or in combination with DMARDs) were upper respiratory tract infections, headache, diarrhea and nasopharyngitis.Pharmaceutical precautions Store below 30°C Reference: US PI April 2014 Date of the document: February 6 2017 It is recommended that patients read patients insert leaflet. Full Prescribing Information is available upon request

Where poor prognostic factors are present. csDMARD=conventional synthetic disease-modifying antirheumatic drug; EULAR=European League Against Rheumatism; RA=rheumatoid arthritis. References: 1. XELJANZ® local product document. 2. Smolen JS, et al. Ann Rheum Dis 2017;76:960–977. 3. Singh JA et al. Arthritis Rheumatol 2016; 68: 1–26. 4. MacFarlane LA, 2014. Kinase inhibitors: the next

generation of therapies in the treatment of rheumatoid arthritis. Int J Rheum Dis17:359-368

®Registered Trademark

The most common serious infections reported with XELJANZ® 5mg twice daily included pneumonia, cellulitis, herpes zoster and urinary tract infection.1

XELJANZ® 5mg twice daily is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. It may be used as monotherapy or in combination with methotrexate or other conventional DMARDs. 1

The ACR* 2015 & EULAR* 2016

GUIDELINES RECOMMEND

XELJANZ® FOR ESTABLISHED RA*

AS AN OPTION AFTER csDMARD

FAILURE2,3

PP-XEL-GLM-0115

*†

*

Under the patronage of H.H. Sheikh Hamdan Bin Rashid Al ... Program.pdf · 19th Asia Paciﬁc...

Documents

Transcript of Under the patronage of H.H. Sheikh Hamdan Bin Rashid Al ... Program.pdf · 19th Asia Paciﬁc...